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1. Introduction
Asthma comes from the Greek word for “panting” and has been described as a pathological
condition for centuries. It is a chronic inflammatory disorder of the airways in which many
immunological cells play a role, including mast cells and eosinophils. In susceptible individ‐
uals, this inflammation causes symptoms which are usually associated with widespread
variable airflow obstruction that is often reversible, either spontaneously or with treatment,
and causes an associated airway hyperresponsiveness (AHR) to a variety of stimuli. The
clinical features of asthma include dyspnea, wheezing and coughing.
During the last forty years there has been an increased understanding of the wide spectrum
of this disease and as a result a number of effective treatments have been developed. Despite
these advances, however, the mortality continues to increase and approximately 500 Canadi‐
ans and 3500 Americans die each year from asthma. It remains a major cause of morbidity, as
the leading cause of school absenteeism and the third leading cause of work absenteeism. The
prevalence of asthma in North America has been on a constant rise over the last 25 years and
it is estimated that currently over 3 million Canadians and 25 million Americans suffer from
asthma. Worldwide the prevalence rates of asthma are rising on average by 50% each decade
and developing a better understanding of the risk factors associated with this trend is critical.
These may be broadly classified as either host genetic factors or environmental factors (Table
1).
One of the marked risk factors of asthma associated with the westernized lifestyle is our
changing diet and/or nutritional status. It has been hypothesized that the significant change
in our diet plays a dominant role in the etiology of asthma. Seaton et al. have proposed that
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asthma prevalence has increased in UK because of an alteration in diet associated with
industrialization [1]. This has lead to a substantial decline in the consumption of fresh fruits,
green vegetables, fish and red meat, and as a result decrease in pulmonary antioxidant defences
and an increase in susceptibility to inhaled irritants and allergens [1]. These foods are the main
sources of antioxidants, substances that protect cells against the effects of free radicals
generated during oxidative stress.
Oxidative stress is important in the pathophysiology of asthma [2] and development of AHR
[3]. A large number of epidemiologic studies have reported the protective effects of dietary
antioxidants such as micronutrients vitamin A, C, and E, polyphenol, and carotenoids against
the development of asthma and decline of lung function. In a study on American children
higher levels of antioxidants beta-carotene and Vitamin C, along with antioxidant trace mineral
selenium is associated with a lower risk of asthma [4]. Dietary vitamin C intake is positively
associated with 1 Second Forced Expiratory Volume (FEV1) in children and adults [5-8] but
less frequently with asthma or wheeze in children and adults [4, 9-11]. Dietary vitamin E intake
is positively associated with ventilatory function [5, 6, 12] but negatively associated with
asthma and wheeze in children [13], adult-onset wheeze [11] and the likelihood of atopic
sensitization in adults [14]. Fresh fruits intake is inversely associated with wheeze [15] and
chronic lung disease onset [16] and is positively associated with FEV1 [17]. Total fruit and
vegetable intake is inversely related to asthma prevalence [18] but not to FEV1 [19] or airway
obstruction [20]. Vegetables may protect against chronic bronchitis, asthma [21], and wheeze
[22]. Moreover, dietary polyphenols intake are associated with lower disease risk with
beneficial clinical outcomes attributed to both the antioxidants and anti-inflammatory
properties of polyphenols [23]. Polyphenols consist of a large group of natural antioxidants
extracted from plants and flavonoids comprise the most studied group.
In addition to antioxidants, intake of fats, particularly the changing composition of polyunsa‐
turated fatty acids (PUFA) in westernized diets, has been implicated in the etiology of asthma.
There has been a reduced intake of saturated fat accompanied by an increase in n-6 PUFA
consumption, particularly linoleic acid and arachidonic acid. In addition, there has been a
decrease in consumption of n-3 PUFA such as eicosapentaenoic acid (EPA) and docosahexae‐
noic acid (DHA). Thus, it has been postulated that the increased ratio of n-6:n-3 PUFA in diets
of industrialized countries may also contributed to the increased asthma incidence.
Genetic Factors Environmental Factors
Atopy
Gender
Genetic predisposition
Race/ethnicity
Smoking
Allergens
Occupational sensitizers
Respiratory infections
Parasitic infections
Perinatal risk factors
Diet and nutrition
Table 1. Risk factors associated with asthma
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Ancient Egyptian papyrus writings contain prescriptions for asthma that include several herbs
suggesting that naturally occurring bioactive compounds may been used to effectively treat
asthma. This chapter summarizes the current knowledge on the effects of dietary compounds
and nutrients on allergy and asthma, with a focus on the mechanisms involved, wherever
possible.
2. Pathogenesis of asthma
Airway inflammation in asthma is a complex process involving the interactions between
immunological mediators produced by inflammatory cells such as mast cells, eosinophils,
basophils, neutrophils, dendritic cells and lymphocytes [24]. This inflammation leads to
structural and architectural changes in the airways of asthmatic patients including collagen
and fibronectin deposition, wall thickening, subepithelial fibrosis and hypertrophy, goblet and
airway smooth muscle cell hyperplasia, and angiogenesis, all of which collectively contribute
to the phenomenon known as airway remodeling [25].
Allergic inflammation is often classified into four phases [26]:
a. Induction of allergic reaction involving antigen uptake, processing and presentation
(Figure 1),
b. Early-phase asthmatic reaction (EAR, Figure 2),
c. Late-phase asthmatic reactions (LAR, Figure 3), and
d. Chronic allergic inflammation (Figure 4)
3. Common molecular targets used in current asthma therapy
Inspite of the advances made in the field of asthma treatments, some patients remain less
responsive to conventional therapies than others. Current treatment strategy includes the
combinations of bronchodilators, particularly short or long acting β2-adrenergic agonists
(SABA, LABA), and inhaled and oral corticosteroids. The current approach to the management
of asthma includes the addition of drugs in a stepwise fashion based on the severity of
symptoms, however the stronger drugs include more severe side effects. The treatment aims
to reverse airflow obstruction and reduces asthma exacerbations thus improving quality of
life. However, long-term use of high dose inhaled corticosteroids therapy may lead to
detrimental effects, such as cataracts [46], osteoporosis in elderly patients [47], and stunting of
growth in children [48]. Moreover, the combination therapy may not modify the disease
progression and are not curative.
The limited efficacy and side effects associated with conventional treatments has lead to the
introduction of nutraceuticals as a “safer“alternative therapy and for those whom symptoms
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are not improved with current therapies. Nutraceuticals is a very general term which encom‐
passes many classifications of food products and derivatives that have the potential to either
prevent or treat pathological conditions in humans or animals. For example, micronutrients
such as vitamins and minerals and non-nutritive components of plant products such as
polyphenols have some anti-inflammatory activity and have been used to supplement some
foods to improve their health benefits. Table 3 summarizes some of the major nutraceuticals
used to treat allergy and asthma currently.
The following sections discuss the current knowledge on the effects of nutraceuticals on
inflammation associated with asthma with a focus on the cellular and molecular mechanism
involved.
3.1. Anti-mediator agents
Anti-mediator agents are a group of drugs that antagonize the release of granule-associated
preformed mediators, lipid mediators, cytokines, chemokines, and growth factors released by
allergen-activated inflammatory cells. Several important groups of specific inhibitors against
many of these inhibitors have been developed.
YYY
Dendritic cell
MHC 
class II
TCR
Naive T cell Th2 cell
IL-4
IL-13
B cell
IgE
Mast cell
Fc  RI receptor
Allergen exposure
Figure 1. AHR and bronchial inflammation starts with the inhalation of an allergen. The allergen enters tissues
through disrupted epithelium. It is then captured by antigen-presenting cells (APCs), usually dendritic cells (DCs), but
also alveolar macrophages and B cells [27]. Allergen-loaded DCs migrate to regional lymph nodes where they present
peptides to naïve T cells [28]. Presentation of processed allergen in the form of peptide fragments on MHC class II
molecules to naïve T cells signals activation and clonal expansion of T cells [27]. In the presence of interleukin (IL)-4,
naïve T cells acquire the characteristic of T helper 2 (Th2) cells [29]. Activated Th2 cells secrete greater amounts of IL-4
and IL-13 which triggers the isotype switch to immunoglobulin (Ig)E synthesis [29, 30]. IgE produced by B cells diffuses
locally, enters the blood and is then distributed systematically. Allergen-specific or non-specific IgE binds to the high-
affinity receptor for IgE (FcεRI) on the surface of tissue-resident mast cells and peripheral blood basophils, thereby sen‐
sitizing them to future allergen exposures [30].
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3.1.1. Lipid mediator blockers
Montelukast is a current FDA approved drug used in asthma treatment and serves a proto‐
typical drug for Lipid Mediator Blocking class of drugs. Its mechanism of actions works
through the blocking of the CysLT receptor for leukotriene D4 which reduces bronchocon‐
striction and inflammation. Zileuton, a related drug in the same class, is a 5-lipoxygenase
inhibitor which blocks the synthesis of cysLTs and leukotriene B4. These drugs while not
natural products serve as a models in the search for nutraceuticals whom may share same or
related mechanism of action and therefore may prove useful in asthma management. Antag‐
onists of the prostaglandin D2 receptors DP1 and CRTH2 reduce inflammation in a murine
model of asthma, possibly by inhibiting prostaglandin synthesis [49, 50]. Antagonist of the
leukotriene B4 receptor BLT1 (R05101576) prevents airway inflammation and AHR in animal
models and non-human primates [51]. Quercetin and luteolin, flavonoids found in fruits,
vegetables and wine, inhibit the release of leukotrienes and PGD2 from human cultured mast
cells [52]. Table 4 summarizes phytochemicals that act on pathways related to the synthesis of
lipid mediators in allergic inflammation.
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Figure 2. The EAR occurs within 30 min of allergen exposure and is principally initiated by mast cell and basophil acti‐
vation [26]. Mast cells are widely distributed throughout the human respiratory tract and are found in large numbers
in the walls of the alveoli and airways [31]. Asthmatics have allergen-specific IgE bound to the FcεRI receptors on mast
cell surface. Upon cross-linking of adjacent IgE molecules by allergen, aggregation of FcεRI triggers a complex intracel‐
lular signaling process [32]. Activated mast cells release a diverse array of biologically active mediators: preformed
granule-associated mediators, lipid-derived mediators, and de novo synthesized cytokines, chemokines, growth fac‐
tors and other biologically active molecules (Table 2) [33]. The release of mast cell-derived mediators contributes to
acute signs and symptoms associated with EAR that may range from mild rhinitis to anaphylactic shock. These media‐
tors induce vasodilation, contraction of the bronchial smooth muscle (producing airflow obstruction and wheezing)
and increased mucus secretion (exacerbating airflow obstruction in the lower airways) [26].
Asthma in the 21st Century — Unexpected Applications of Ancient Treatments
http://dx.doi.org/10.5772/56428
281
Th2 cell
Mast cell
Neutrophil Eosinophil Basophil
Airway smooth 
muscle cells Blood 
vessel
Epithelial 
cells
Bronchoconstriction Vasodilation Mucus production
IL-13CysLTs
MMPs
TNF
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IL-13, IL-5
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IL-13
Figure 3. The LAR typically develops 2-6 hr following allergen challenge, often peaks after 6-9 hr, and has a more se‐
vere and prolonged phase. In general, allergen activated mast cells release various de novo synthesized cytokines, che‐
mokines and growth factors, which are released more slowly than granule-associated mediators [34]. Thus, LAR is
sustained by de novo synthesized mast cell-derived mediators which recruit inflammatory cells to the airways several
hours after allergen challenge. These recruited cells include effector cells, such as eosinophils, basophils, neutrophils,
macrophages, T cells, and DCs [34, 35]. These inflammatory cells are activated when they reach the airway and pro‐
duce a vast array of inflammatory mediators that act on specific receptors and exacerbate airway inflammation and
airway remodeling. Eosinophils are the central effector cells in the LAR [36], and are present not only in the airway
wall [37] but are also found in large numbers in the sputum and bronchoalveolar lavage fluid (BALF) [38]. Eosinophils
are a rich source of granule basic proteins (EBP), such as major basic proteins (MBP), eosinophil cationic protein (ECP),
eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN), and can also generate lipid-mediators (prosta‐
glandins and cysteinyl leukotrienes), cytokines (such as TNF, TGF-β, IL-4 and IL-13) and chemokines [39]. These eosino‐
phil-derived products promote some of the pathophysiological hallmarks of asthma such as AHR [40]. The activation
of peripheral blood neutrophils during allergen challenge results in their intravascular migration, adhesion to the en‐
dothelium, and migration to the site of inflammation and can be responsible for significant damage. Nocturnal asth‐
ma is associated with high levels of neutrophils, which correlate with the severity of the disease [41]. Furthermore, in a
small number of patients who died of sudden-onset asthma, the predominant cell type in the sputum is the neutro‐
phils, not eosinophils [42]. Neutrophils also predominate more frequently in the sputum of patients with acute exacer‐
bations of asthma, mostly associated with respiratory tract infection [43]. T cells are not only important during the
induction phase, but play also a very important role during ongoing inflammation. Th2 cells and their cytokines are
crucial for promoting acute hypersensitivity responses, and for maintaining the state of chronic and relapsing eosino‐
phil-predominant inflammation that is characteristic of chronic allergic inflammation. Elevated levels of CD4+ T cells
are observed in the bronchial mucosa of biopsy samples, BALF and sputum from patients with asthma [44]. In a major‐
ity of studies, T cells found in asthmatic patients express cytokines or transcription factors characteristic of Th2 cells,
especially IL-4, IL-5, IL-9 and IL-13 [45].
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Antioxidants
Vitamin A
CH3
H3C CH3
OH
CH3 CH3
Vitamin A (retinoid) occurs in many foods,
including carrots, broccoli, sweet potato,
butter, spinach, pumpkin, and liver, cod liver
oil. The form found in colorful fruits and
vegetables is called provitamin A carotenoid.
Vitamin C
O O
OHHO
HO
HO H
Vitamin C (ascorbic acid) is an essential
nutrient for humans as it protects the body
against oxidative stress and is a necessary in
collagen synthesis. Fruits (kakadu plum,
camu camu, rose hip, indian gooseberry,
blackcurrant, orange, tangerine, and guava)
and vegetables (green and red chilli pepper,
red pepper, broccoli, Brussels sprout,
spinach, and cabbage) are good sources of
Vitamin C.
Vitamin E
Vitamin E is a fat-soluble vitamin that exists
in eight different forms. It consists of a group
of substances belonging to two closely
related families, the tocopherols and
tocotrienols, with each existing in a number
of isomeric forms (α, β, γ, and δ). α-
tocopherol is the most active form of Vitamin
E in humans and is considered the major
Class of Product Examples Biological Effects
Preformed Mediators Histamine, heparin Increase vascular permeability,
smooth muscle contraction
Enzymes Tryptase, chymase, cathepsin G,
carboxypeptidase
Remodel tissue matrix
Cytokines IL-4, IL-13 Stimulate Th2 cell response
IL-3, IL-5, GM-CSF Promote eosinophil production and
activation
Tumor necrosis factor (TNF) Promotes inflammation and cytokine
release by immune cells
Chemokines CCL2, CCL3, CCL4, CXCL1,
CXCL2, CXCL3, CXCL10
Attract monocytes, macrophages and
neutrophils
Lipid Mediators Prostaglandin D2, E2
Leukotriene B4, C4
Cause smooth muscle contraction, increase
vascular permeability, stimulate mucus
secretion
Platelet-activating factor Attracts leukocytes, amplifies production of
lipid mediators, activates neutrophils,
eosinophils and platelets
Table 2. Mast cell-derived proinflammatory mediators
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Antioxidants
membrane-bound antioxidant employed by
cells. Its main antioxidant function is
protection against lipid peroxidation. There
is an interaction between Vitamin E and
other nutrients, particularly selenium and
vitamin C in the antioxidant role.
Vitamin E is found in fruits (tomato, mango,
and papaya), green leafy vegetables (lettuce,
spinach, turnip, and beet), nuts and nut oils
(almonds and hazelnuts), vegetable oils
(wheat germ oil, sunflower oil, and safflower
oil), meat, and poultry.
Vitamin D
CD2
HO
D
CH3
H3C
OH
CH3
H
H
H3C
Flavonoids
O
O
Flavones
Flavonoids constitute the most important
single group of polyphenols of low
molecular weight polyphenolic secondary
plant metabolites, with more than 8,000
compounds described. They are found in
fruits, vegetables, nuts, seeds, stems, flowers,
roots, tea, wine, and coffee and are common
substances in our daily diet. Their structure is
a heterocyclic hydrocarbon, chromane, and
substitution of its ring C in position 2 or 3
with a phenyl group (B-ring) results in flavans
or isoflavans. An oxo-group in position 4
leads to flavanones and isoflavanones. The
presence of a double bond between C2 and
C3 provides flavones and isoflavones. An
additional double bond in between C1 and
C2 makes these compounds colourful
anthocyanidins. Based on their structure,
flavonoids are categorized into eight groups:
O
O
Isoflavones
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Antioxidants
O
O
OH
Flavonols
flavans, flavanones, isoflavanones, flavones,
isoflavones, anthocyanidins, chalcones, and
flavonolignans (Table 11].
Resveratrol
HO
OH
OH
Resveratrol is a stilbenoid, a type of natural
phenol, and a phytoalexin produced
naturally by several plants when under
attack by pathogens such as bacteria or
fungi. Resveratrol is found in the skin of red
grapes and in other fruits. It is sold as a
nutritional supplement derived primarily
from Japanese knotweed.
Selenium
Selenium is derived from both vegetable and
animal products, particularly seafood, liver,
and cereals. As a member of the sulfur family
of elements, it shares several chemical
properties with sulfur, including valence
states and the ability to form covalent bonds
with carbon. It is unique among antioxidants
in that it exerts its biological effects through
direct incorporation into proteins
(selenoproteins) as the amino acid
selenocysteine. Some selenoproteins that
have been characterized as important
antioxidant enzymes include GPX-1, GPX-4,
thioredoxin reductase-1 and thioredoxin
reductase-2, and selenoprotein P. The
selenium-dependent enzyme, GPX recycles
glutathione, reducing lipid peroxidation by
catalyzing the reduction of peroxides,
including hydrogen peroxide.
Avenanthramid
e
HO
OHO
N
H
R
OH
O
Oats contain unique, low-molecular-weight,
soluble phenolic compounds called
avenanthramides (Avns), which are not
present in other cereal grains. These
compounds are antipathogens
(phytoalexins), which are produced by the
plant in response to exposure to pathogens
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Antioxidants
such as fungi. Avns are conjugates of a
phenylpropanoid with anthranilic acid or 5-
hydroxy anthranilic acid. More than 20
different forms of Avns are present when
extracted from oats, and the three major
forms are A, B, and C.
Table 3. Some of the dietary nutraceuticals indicated in asthma prevention.
Phytochemicals
Flavonoids Target/Function
4,3’,5’-trihydroxystilbene Inhibits Cyclooxygenase 1
4,3’-dihydoxy-
5’methoxystilbene
inhibits Cyclooxygenase 1
4-hydoxy-3’5’-dimethoxystilbene Inhibits Cyclooxygenase 1
Acacetin Inhibits Cyclooxygenase 1
Andanthoflavone Inhibits 12-Lipoxygenase, 15-Lipoxygenase
Apigenin Inhibits Cyclooxygenase 2, 12-Lipoxygenase, 15-Lipoxygenase
Artonin E Inhibits Cyclooxygenase 1, 5-Lipoxygenase, 12-Lipoxygenase, 15-
Lipoxygenase
Baicalein Inhibits Cyclooxygenase 1, Cyclooxygenase 2, 5-Lipoxygenase, 12-
Lipoxygenase, 15-Lipoxygenase
Bicalin Inhibits Cyclooxygenase 1, Cyclooxygenase 2
Buddledin A Inhibits Cyclooxygenase 1
Chrysin Inhibits Cyclooxygenase 1, 5-Lipoxygenase
Chrysol Inhibits 5-Lipoxygenase
Cirsiliol Inhibits 5-Lipoxygenase, 12-Lipoxygenase
Daidzein Inhibits Cyclooxygenase 2
Epicatechin Inhibits 5-Lipoxygenase
Epigallocatechin Inhibits 5-Lipoxygenase
Fisetin Inhibits Phospholipase A2, 5-Lipoxygenase, 12-Lipoxygenase, 15-
Lipoxygenase
Flavone Inhibits 5-Lipoxygenase
Gambogenic acid Inhibits Cyclooxygenase 2
Genistein Inhibits Cyclooxygenase 2
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Ginkgetin Inhibits 5-Lipoxygenase
Glycitein Inhibits Cyclooxygenase 2
Isoliquiritigenin Inhibits Cyclooxygenase 1, Cyclooxygenase 2
Kampferol Inhibits Phospholipase A2
Kaempferol Inhibits 5-Lipoxygenase
Kenusanone A Inhibits 5-Lipoxygenase
Kisetin Inhibits Phospholipase A2
Kuraridin Inhibits Cyclooxygenase 1, 5-Lipoxygenase
Kurarinone Inhibits Cyclooxygenase 1, 5-Lipoxygenase
Kuwanon C Inhibits 5-Lipoxygenase, 12-Lipoxygenase
Luteolin Inhibits 5-Lipoxygenase, 15-Lipoxygenase
Morelloflavone Inhibits Phospholipase A2
Morusin Inhibits Cyclooxygenase 1, 12-Lipoxygenase
Mosuin Inhibits 15-Lipoxygenase
Myricetin Inhibits 5-Lipoxygenase
Narigenin Inhibits Phospholipase A2, 5-Lipoxygenase
Oroxidin Inhibits 5-Lipoxygenase
Pedalitin Inhibits 5-Lipoxygenase
Quercetin Inhibits Cyclooxygenase 1, Cyclooxygenase 2, 5-Lipoxygenase, 12-
Lipoxygenase
Resveratrol Inhibits Cyclooxygenase 1, Cyclooxygenase 2, 5-Lipoxygenase
Rhamnetin Inhibits 5-Lipoxygenase
Sanggenon B Inhibits Cyclooxygenase 1, 5-Lipoxygenase
Sanggenon D Inhibits 5-Lipoxygenase
Scutellarein Inhibits Phospholipase A2
Silibinin Inhibits 5-Lipoxygenase
Sophoflavanone A Inhibits Cyclooxygenase 1
Sophoflavanone G Inhibits Cyclooxygenase 1, 5-Lipoxygenase, 12-Lipoxygenase
Tectorigenin Inhibits Cyclooxygenase 2
Wogonin Inhibits Cyclooxygenase 2
Polyphenols
Anisic acid Inhibits Phospholipase A2
Caffeic acid Inhibits 5-Lipoxygenase
Catechin Inhibits Cyclooxygenase 1, 5-Lipoxygenase
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Curcumin Inhibits Phospholipase A2, Cyclooxygenase 1, Cyclooxygenase 2, 5-
Lipoxygenase
Diphyllin acetapioside Inhibits 5-Lipoxygenase
EGCG Inhibits Cyclooxygenase 2
Eugenol Inhibits 5-Lipoxygenase
Gingerol Inhibits 5-Lipoxygenase
Ginkgetin Inhibits Phospholipase A2, 5-Lipoxygenase
Hydroxytyrosol Inhibits 5-Lipoxygenase
Hyperforin Inhibits 5-Lipoxygenase
Medicarpin Inhibits 5-Lipoxygenase
Ohenethyl ferulate Inhibits Cyclooxygenase 2
Onosmins A and B Inhibits 5-Lipoxygenase
Panaxynol Inhibits 5-Lipoxygenase
Phenethyl ferulate Inhibits 5-Lipoxygenase
Quercetagetin-7-O-beta-O-glucoside Inhibits 5-Lipoxygenase
Rosmarinic acid Inhibits 5-Lipoxygenase
Rosmarinic acid methylester Inhibits 5-Lipoxygenase
Rosmarol Inhibits Cyclooxygenase 20
n-3 PUFA Inhibits Cyclooxygenase 2 and 5-Lipoxygenase
Table 4. Phytochemical inhibitors of lipid mediators
3.1.2. Cytokines blockers
Cytokines exhibit pleiotropy and have overlapping functions in the pathogenesis of asthma,
making them a major target for new asthma therapies. Allergic inflammation is driven by an
imbalance between Th1 and Th2 cytokines, favoring the Th2 arm of the immune response and
inhibition of Th2 cytokines IL-4, IL-5 and IL-13 prevents asthma progression in animal models.
Anti-IL-4 administration in mice prevents development of acute and chronic allergic inflam‐
mation [53], therefore, natural products that specifically target cytokines or their receptors
have the potential to be effective asthma treatments.
Our current pharmacological approach include the use humanized monoclonal antibodies
against specific cytokine or receptor targets. This class of drugs, known as the biologics, has
been approved for use in treatment of cancer, autoimmune and inflammatory diseases.
Omalizumab is a drug currently approved for the management of asthma and is antibody
targeting IgE. While not specifically a cytokine blocker it functions through the same mecha‐
nism of action. These drugs while very effective carry the risk of unforeseen side effects and
under current production treatment costs remain very high ranging upwards from $15,000 to
60,000 per annum. Others examples including humanized IL-4-specific antibodies that block
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IL-4 receptor α that are under clinical trial [54]. Neutralizing antibodies against IL-5 (Mepoli‐
zumab and Reslizumab) and IL-5 receptor α (MEDI-563) remarkably inhibits IL-5 related
pathways resulting in reduction of asthma exacerbations [55]. Tralokinumab, an anti-IL-13
monoclonal antibody, prevents the development of asthmatic phenotype, both in murine
model as well asthmatic patients [56]. Suplatast tosilate inhibits IL-4 and IL-5 production from
T cells and reduces AHR in asthmatic patients.
Some of the phytochemicals and potential treatments indicated against cytokines function are
listed in Table 5. These products if proved to be effective, could be cost effective alternatives
and being natural products have the potential to have less side effects.
Phytochemicals
Anti-oxidants Target/Function and Effective Concentration(s) References
Vitamin A Inhibits release of Th2 cytokines IL-4, IL-5 and IL-13 in vitro as well as invivo. Suppresses production of IP-10, IL-6, TNF, GM-CSF and IFN-γ.
Vitamin C Effect on Th1/Th2 balance controversial.
Vitamin E Inhibits IL-1β, IL-6 and TNF response of human monocytes in asthmaticpatients. Suppresses IL-4 levels in lungs of experimental allergic mice.
Flavonoids
Apigenin
Reduces airway inflammation by down-regulating Th2 cytokines IL-4
and IL-13. Suppresses the expression of Th2 cytokines (IL-4, IL-13 and
IL-5) in human basophils. Inhibits production of TNF, IL-6 and GM-CSF
in HMC-1 cells.
[57, 58]
Baicalein
Decreases inflammatory cytokines such as TNF and IL-6 in allergic
inflammation. Inhibits production of IL-6 in activated human mast
cells, and GM-CSF from human cultured mast cells.
[52, 59]
Bicalin Reduces TNF and IL-6 levels in plasma and BALF in cigarette smoke-induced COPD rat model. [60]
Chrysin
Downregulates IL-4 and IL-13 expression and production in allergen-
sensitized mice. Inhibits TNF, IL-1β, IL-4 and IL-6 expression in RBL-2H3
and HMC-1 cells.
[61]
Chrysol Inhibits IL-4 production in antigen-stimulated RBL-2H3 cells. [62]
Daidzein Mast cell stabilizer; inhibits Th2 cytokines production.
Fisetin
Inhibits IL-13 production in RBL-2H3 cells, and TNF, IL-6, IL-4 and IL-1β
production in HMC-1 cells. Suppresses the expression of Th2 cytokines
(IL-4, IL-13 and IL-5)in human basophils. Attenuates LPS-induced TNF,
IL-6 and IL-10 release in leukocytes of patients with COPD.
[57, 63-65]
Genistein Inhibits TNF production in PBMCs from asthmatic patients.
Ginkgetin Inhibits TNF expression in activated macrophages.
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Phytochemicals
Anti-oxidants Target/Function and Effective Concentration(s) References
Isoliquiritigenin Inhibits the release of TNF and IL-6 in activated inflammatory cells.
Kaempferol
Impairs Th2 cytokines production (IL-5 and IL-13) in OVA-sensitized
mice. Suppresses the release of IL-4 and TNF in RBL-2H3 cells and
macrophages. Inhibits IgE-mediated TNF and IL-6 release in hCBMCs.
Kuraridin Suppresses expression of TNF and IL-1β in LPS-stimulatedmacrophages (40 μM). [66]
Kurarinone Suppresses expression of TNF and IL-1β in LPS-stimulatedmacrophages (40 μM). [66]
Luteolin
Reduces the levels of TNF and IL-1β in LPS-stimulated macrophages (8
& 16 μM). Inhibits induction of TNF, IL-6 and GM-CSF in HMC-1 cells
(10 & 50 μM). Inhibits Th2 cytokines (IL-4, IL-5 and IL-13) expression in
murine asthma model (50 & 100 mg/kg body wt.). Inhibits myelin
basic protein-induced IL-6, TGF-β1, and TNF release in hCBMCs (10 &
100 μM). Decreases TNF (IC50 7.9±4.6 μM) and IL-1β (IC50 5.1±0.4 μM)
in PBMCs. Reduces IL-4 and IL-5 levels in BALF of murine asthma
model (0.1 mg/kg body wt.). Inhibits antigen-IgE-mediated TNF (IC50
5.8 μM) and IL-4 (IC50 3.7 μM) production in RBL-2H3 cells.
[57, 67-73]
Morin Inhibits IgE-mediated TNF and IL-6 release in hCBMCs (10 & 100 μM).Inhibits TNF secretion in LPS-activated macrophages. [74, 75]
Myricetin
Inhibits TNF (30 μM) and IL-6 (30 μM) production in HMC-1 cells.
Inhibits IgE-mediated TNF (10 & 100 μM) and IL-6 (1, 10 & 100 μM)
release from hCBMCs.
[75, 76]
Naringenin
Suppresses Th2 cytokines production from CD4 T cells (0.8 mg/kg
body wt.). Reduces IL-4 (25, 50 & 100 mg/kg body wt.) and IL-13 (50 &
100 mg/kg body wt.) levels in BALF of murine asthma model.
Suppresses LPS-induced IL-1β (10, 25 & 50 μg/mL), IL-6 (5, 10, 25 & 50
μg/mL), and TNF (25 & 50 μg/mL) production in macrophages and
human whole-blood samples.
[77-79]
Pedalitin Inhibits TNF and IL-12 production in LPS-activated macrophages (40μM). [80]
Quercetin Inhibits IgE-mediated TNF (10 & 100 μM) and IL-6 (1, 10 & 100 μM)release from hCBMCs. [75]
Resveratrol
Inhibits increase in Th2 cytokines (IL-4 and IL-5) in plasma and BALF in
asthmatic mouse model (30 mg/kg body wt.). Inhibits TNF induced
GM-CSF and VEGF release in HASM cells. Inhibits PMA- and A23187-
induced TNF and IL-6 release in HMC-1 cells. Decreases production of
IL-1β in lung tissue of mice with LPS-induced acute lung injury (1
[68, 81-86]
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Phytochemicals
Anti-oxidants Target/Function and Effective Concentration(s) References
mg/kg body wt.). Attenuates C5a-induced TNF, IL-1β and IL-6
production in mouse model (10 mg/kg body wt.).
Scutellarein Inhibits TNF and IL-12 production in LPS-activated macrophages (40μM). [80]
Silibinin
Polarizes Th1/Th2 balance towards Th1 by increasing IFN-γ (200 & 400
mg/kg body wt.) and decreasing IL-4 levels (200 & 400 mg/kg body
wt.) in asthmatic mouse model.
[87]
Polyphenols
Caffeic acid
Inhibits increase in TNF and Th2 cytokines (IL-4 and IL-5) in BALF in
asthmatic mouse model (10 mg/kg body wt. IP). Inhibits IL-10
expression in allergic patients’ DCs (10 μM). Suppresses TNF and IL-6
levels in asthmatic patients (13% solution).
[88-90]
Curcumin
Attenuates the expression of IL-4 and IL-5 in BALF in asthmatic mouse
model (20 mg/kg body wt.). Inhibits release of IL-10, TNF and IL-1β in
HDM-activated eosinophils and bronchial epithelial cells (10 μM).
Inhibits IL-5, GM-CSF and IL-4 production in lymphocytes from
bronchial asthmatics (10 μM). Inhibits TNF secretion in activated
HMC-1 cells (10 & 100 μM/L). Inhibits tryptase-induced IL-6 release in
eosinophils (25 μM).
[91-95]
EGCG
Reduces TNF in BALF in asthmatic guinea pigs (25 mg/kg body wt. SC).
Inhibits TNF and IL-6 production in HMC-1 cells (100 μM). Attenuates
production of TNF in lungs of mice with LPS-induced acute lung injury
(10 mg/kg body wt. IP).
[96-99]
Eugenol Inhibits IL-1β, TNF and IL-6 release in macrophages. [100, 101]
Gallic acid Inhibits TNF and IL-6 in HMC-1 cells (10 μM). [102]
Gingerol Inhibits IL-1β and IL-12 release in peritoneal macrophages 100 ng/mL) [103]
Hydroxytyrosol Inhibits LPS-induced TNF production in THP-1 cells (25, 50 & 100 μM).Reduces TNF levels in LPS-treated mice. [104, 105]
Rosmarinic acid
Reduces IL-4, IL-5 and IL-13 expression in lung of HDM-sensitized
asthmatic mouse model (1.5 mg/day PO). Attenuates IL-1β, IL-6, and
TNF increase in spleen and nasal mucosa of asthmatic mouse model (4
mg/kg body wt.). Inhibits IL-4 and IFN-γ release from CD4+ T cells (1 &
5 μM). Inhibits diesel exhaust particles-induced IL-1β expression in
mice lung (4.6 μg/kg body wt.).
[106-110]
Terpenes
Celastrol Reduced mRNA expression of IL-5, IL-5, IL-13, TNF, and IFN-γ in BALcells and lung tissue of asthmatic mouse model.
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Phytochemicals
Anti-oxidants Target/Function and Effective Concentration(s) References
Costunolide Inhibits production of TNF, IL-1β and IL-6 by LPS-stimulatedmacrophages (0.1, 0.5 & 1 μM). [111, 112]
Helenalin Inhibits TNF and IL-6 secretion by ASMCs (1 μM). [113]
n-3 PUFA
EPA and DHA Lower BALF concentration of pro-inflammatory
cytokines IL-1α, IL-2, IL-5, IL-9, IL-13, G-CSF and RANTES.
EPA (120 μM) suppress TNF and IL-1β expression and production in
LPS-stimulated alveolar macrophages from asthmatic patients
Ref?
Table 5. Phytochemical inhibitors of proinflammatory cytokines
3.1.3. Chemokines and chemokine receptors blockers
Chemokines (CC) and their receptors (CCR) play a crucial role in the recruitment of inflam‐
matory cells into the airways and development of asthma. CC-chemokine receptor 3 CCR3,
CCR4, and CRTH2 antagonists are being targets currently being evaluated for the treatment
of asthma. A study found that treatment of asthmatic mice with an anti-CCR3 monoclonal
antibody inhibits allergen-induced eosinophilia and CD34+ progenitor cell infiltration into the
lung, which is accompanied by reduced AHR [114, 115]. RS-1748, a CCR4 antagonist, inhibits
OVA-induced airway inflammation in guinea pigs [116]. The number of CCR4-expressing Th2
cells is increased in the airways of asthmatic patients which can be blocked by a selective CCR4
antagonist [117], and therefore could be an effective therapy for asthma. Ramatroban and
closely related TM30089 are antagonists for CRTH2, a chemokine receptor expressed on Th2
cells. They have been shown to attenuate allergen-induced EAR and LAR in animal models of
asthma [118, 119]. Some of the phytochemicals indicated against chemokines function are listed
in Table 6.
Phytochemicals
Flavonoids Target/Function and Effective Concentration(s) References
Apigenin
Suppresses the production of MDC and IP-10 in THP-1 cells (10-6
and 10-5 M). Inhibits release of LPS-induced MCP-1 in J774.2
macrophages (10 & 30 μM). Inhibits production of IL-8 in HMC-1
cells.
[58, 120, 121]
Baicalein
Inhibits IL-8 and MCP-1 release in activated human mast cells.
Inhibits eotaxin production in human dermal fibroblasts (10 μg/
mL).
[59, 122]
Baicalin
Reduces IL-8 levels in plasma and BALF in cigarette smoke-induced
COPD rat model. Inhibits eotaxin production in human dermal
fibroblasts (10 μg/mL).
[60, 122]
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Phytochemicals
Flavonoids Target/Function and Effective Concentration(s) References
Chrysin Inhibits TNF-induced IL-8 expression in HEK 293 cells (20, 40 & 80μM). [123]
Chrysol Inhibits MCP-1 production in antigen-stimulated RBL-2H3. [62]
Fisetin Inhibits TNF-induced IL-8 expression in HEK 293 (20, 40 & 80 μM).Inhibits IL-8 production in HMC-1 cells. [65, 123]
Genistein
Blocks HDM-induced IL-8 release in human lung epithelial cells (50
μM). Inhibits IL-8 release in TNF-stimulated human keratinocytes
(60 μM). Inhibits chemokine-stimulated eosinophil adherence (10-7,
10-6 and 10-5 M).
[124-126]
Isoliquiritigenin Inhibits eotaxin-1 secretion in human fetal lung fibroblasts (IC500.92±0.05 μg/mL). [127]
Kaempferol
Suppresses LPS-induced production of MDC, IP-10 and IL-8 in
THP-1. Inhibits MCP-1 production in antigen-stimulated RBL-2H3
and J774.2 macrophages (10 & 30 μM). Inhibits TNF-induced IL-8
expression in HEK 293 (20, 40 & 80 μM).
[62, 123, 128, 129]
Kuraridin Suppresses expression of MCP-1 in LPS-stimulated macrophages (40μM). [66]
Kurarinone
Inhibits MCP-1-induced chemotaxis of THP-1 cells (IC50 19.2 µg/mL).
Suppresses expression of MCP-1 in LPS-stimulated macrophages (40
μM).
[130]
Luteolin
Inhibits TNF-induced expression of MCP-1 (10, 20 & 30 μM) and
CXCL-1 (20 & 30 μM) expression in keratinocytes. Inhibits induction
of IL-8 in activated HMC-1 cells (50 μM) and hCBMCs.
[70, 131, 132]
Morin Inhibits IL-8 production in antigen-stimulated hCBMCs (100 μM). [75]
Myricetin Inhibits IL-8 production in antigen-stimulated hCBMCs (100 μM). [75]
Naringenin
Decreases secretion of PMA-induced IL-8 in HL-60 cells (20 μM).
Suppresses LPS-induced IL-8 production by macrophages and
human whole-blood samples (25 & 50 μg/mL). Inhibits expression
of RANTES and eotaxin-1 in BALF and lungs in asthmatic mouse
model (50 & 100 mg/kg body wt.).
[78, 79, 133]
Quercetin
Decreases production of IL-8 (3 & 30 μM) and MCP-1 (10-4, 10-5 and
10-6 M) in activated HMC-1 and IL-8 in human bronchial epithelial
cells (0.1, 10 & 25 μM).
[134-136]
Resveratrol
Decreases production of MIP-1α in lung tissue of mice with LPS-
induced acute lung injury (10 mg/kg body wt.). Reduces TNF-
induced IL-8 release in HASMCs in COPD. Inhibits IFNγ-induced
production of IP-10 and MIG in macrophages and HMC-1 cells.
[68, 82, 83, 85, 86,
137]
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Phytochemicals
Flavonoids Target/Function and Effective Concentration(s) References
Inhibits IL-8 production in THP-1 cells (0.1, 1, 10 & 100 μg/mL).
Attenuates C5a-induced MIP-1α production in mouse model (1
mg/kg body wt.).
Tectorigenin Inhibits MCP-1 expression in endothelial cells. [138]
Wogonin Suppresses mite antigen-induced TARC expression in humankeratinocytes (250 ng/mL). [139]
Polyphenols
Caffeic acid
Decreases IL-8 release in chitinase-activated human airway
epithelial cells (1 μM). Inhibits production of eotaxin in human lung
fibroblast cells (1, 10 & 100 μM). Inhibits IP-10 expression in allergic
patients’ DCs (10 μM). Decreases expression of CXCR4 receptor on
CD4 T cells (20 μg/mL). Suppresses IL-8 levels in asthmatic patients
(13% soln.).
[89, 90, 140-143]
Curcumin Inhibits tryptase-induced IL-8 release in eosinophils (25 μM).
EGCG
Inhibits IL-8 release in TNF-stimulated human keratinocytes (0.5, 1,
5 & 10 μM). Reduces airway inflammation in asthmatic mouse
model by binding to chemokines CXCL9, CXCL10 and CXCL11 (10 &
100 μM). Decreases MCP-1 and CCR2 expression on THP-1 cells (100
μM). Attenuates production of MIP-2 in lungs of mice with LPS-
induced acute lung injury. Reduces expression of MCP-1 and IL-8 in
HMC-1 cells (100 μM). Inhibits neutrophil migration by suppression
of CINC-1 production (15, 50 & 150 μg/mL). Downregulates
cigarette smoke-induced IL-8 release from bronchial epithelial cells.
[97, 99, 125,
144-147]
Gallic acid
Inhibits production of IL-8 and TARC (5 & 10 μg/mL) in neutrophils
and keratinocytes respectively. Inhibits eotaxin and RANTES in
pleural lavage fluid of allergen-challenged mouse model (100
mg/kg body wt.). Inhibits IL-8 release in HMC-1 cells (10 μM).
[148-150]
Rosmarinic acid
Inhibits LPS-induced production of MCP-1 and MIP-1α in bone-
marrow derived DCs (100 μM). Reduces diesel exhaust particles-
induced MIP-1α, MCP-1 and KC expression in mice lung (4.6 μg/kg
body wt.). Inhibits expression of eotaxin in lungs of mite antigen-
sensitized mice (1.5 mg/kg body wt. PO). Inhibits expression of
CCL11 and CCR3 genes induced by TNF in human dermal fibroblast
cells.
[102, 107, 110, 151]
Helenalin Inhibits eotaxin and RANTES secretion in ASMCs (1 μM). [113]
Table 6. Phytochemical inhibitors of chemokines
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3.1.4. Miscellaneous: IgE, histamine, enzymes
The activation of mast cells involves the cross-linking of IgE bound to the FCεRI surface
receptor. Activation is measured in the laboratory by the release of the Beta-hexosaminidase
enzyme (β-hex) from cytosolic granules into the interstitial fluid. The following compounds
(Table 7) have been found to be inhibitors of β-Hex release in vitro and have to potential to be
inhibitor of IgE-antigen activation.
Phytochemicals IC50 References
Anti-oxidants
Vitamin A/carotenoid ? [152]
Flavonoids
Apigenin 4.5 μM [153]
Baicalein 17 μM [153]
Chrysin ? [62]
Daidzein ? [83]
Fisetin 3 μM [73]
Genistein 28.5 μg/mL [83]
Ginkgetin 6.52 μM [154]
Glycitein 28.5 μg/ml [83]
Isoliquiritigenin 24 μM [155]
Kaempferol 7.5 μM [62]
Luteolin 3 μM [73]
Morin 51 μM [153]
Myricetin 6.7 μM [153]
Naringenin 29 μM [156]
Quercetin 3 μM [73]
Resveratrol 14 μM [157]
Sophoflavanone G 20 μM [158]
Tectorigenin 0.193 mM [159]
Polyphenols
Caffeic acid ? [160]
Curcumin 5.3 μM [161]
EGCG ? [162]
Ginkgetin ?
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Phytochemicals IC50 References
Medicarpin >100 μM [155]
Rosmarinic acid ? [160]
Terpenes
Celastrol ? [163]
Costunolide 34 μM [164]
Table 7. Phytochemical inhibitors of beta-hexosaminidase enzyme
3.2. Inhibitors of intracellular signaling pathways
The previous section focused on compounds that affected the function of extracellular, cell
surface/receptor and cell to cell interactions. The following group of compounds affect the
intercellular functions of the cells particular the components of cell signalling pathways.
3.2.1. Protein kinase inhibitor
Protein kinases have a key role in the expression and activation of inflammatory mediators
implicated in airway inflammation. Enhanced activation of p38 mitogen-activated protein
kinase (MAPK), c-Jun N-terminal kinase (JNK), spleen tyrosine kinase (Syk), and phosphoi‐
nositol 3-kinase (PI3K) signaling pathways have all been proposed to have a role in the
pathogenesis of asthma.
p38 MAPK is involved in the airway inflammation and remodeling. A selective synthetic p38
MAPK inhibitor SB2439063 reduces synthesis of Th2 cytokines [54] and thus has a potential
application in asthma treatment. Inhaled p38 MAPK antisense oligonucleotide attenuates
asthma in OVA-sensitized and –challenged mice [165]. The natural product limonene inhibits
eosinophil migration in p38 MAPK dependent manner and was investigation in an in vitro
bronchial asthma model [166].
JNK activity is increased in corticosteroid-resistant asthma and SP600125, a JNK inhibitor,
reduces cytokines expression and inflammatory cells accumulation in BALF of asthmatic
animal models. Celastrol, a natural compound, modulates the expression of JNK in asthma
[167]. It supresses allergen-induced mouse asthma by decreasing expression of MAP kinases,
ERK and JNK [168].
Syk is a protein kinase involved in signal transduction in many inflammatory cells, and its
aberrant regulation is associated with asthma, thus is considered an interesting target for
asthma therapies. BAY 61-3606, a synthetic Syk inhibitor, inhibits inflammatory mediator
release from mast cells, basophils, eosinophils, and monocytes, and reduces allergic asthma in
rats [169]. Eupatilin, a biological extract, inhibits Syk and blocks downstream signaling
pathways in mast cell from guinea pig lung tissues, leading to inhibition of mediator release
[170]. Thus, Syk inhibitors may have use clinically as a treatment for asthma.
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The PI3K pathway plays a major role in the pathogenesis of asthma by promoting eosinophil
and neutrophil recruitment and degranulation [171]. Sorbus commixta water extract, an anti-
inflammatory medicinal plant, remarkably blocks PI3K activity in antigen-activated macro‐
phages, suggesting the usefulness of PI3K inhibitors in asthma [172].
3.2.2. Transcription factor inhibitors
The increased expression of various inflammatory proteins seen in asthma is the result of
enhanced gene transcription, since many of the genes are not expressed in normal cells but are
selectively induced during inflammation. Changes in gene transcription are under the control
of transcription factors which therefore play a key role in the pathogenesis of asthma.
Transcription factors such as nuclear factor-κB (NF-κB), GATA-3, signal transducers and
activators of transcription protein (STAT)s, nuclear factor of activated T cells (NFAT), and
peroxisome proliferator-activated receptors (PPAR) have been implicated in asthma and
therefore represent therapeutic targets.
NF-κB is induced by many factors involved in asthmatic inflammation and is implicated in
glucocorticoid-resistant asthma. Inhibition of IκB (inhibitor of NF-κB) by small molecule
inhibitors suppresses inflammatory responses in mast cell [173], OVA-induced rat model of
airway inflammation [174], and macrophages from BALF of asthmatic patients. A number of
herbal preparations (i.e. andrographolide and narigenin) have been demonstrated to inhibit
airway inflammation and AHR by inhibiting NF-κB activity in OVA-induced murine asthma
[78, 175]. Many inhibitors of NF-κB have been identified belonging to the Flavonoids, Poly‐
phenols and Terpenoids classes of compounds as well as n-3 PUFA (see Table 8).
Flavonoid Polyphenols Terpenoids PUFA
Apigenin
Capsaicin
Fisetin
Kuraridin
Kurarinone
Luteolin
Myrecitin
Naringenin
Quercetin
Resveratrol
CAPE
Curcumin
Epigallocatechin-3-gallate
Gallic acid
Gingerol
Rosmarinic acid
Parthenolide
Costunolide
Helenalin
Celastrol
Celaphanol A
Kamebanin
Kamebacetal A
Excisanin A
Orbiculin
n-3 PUFA
Table 8. Naturally occurring NF-κB inhibitors
GATA-3 is a critical transcription factor that is specifically expressed by Th2 cells and is
involved in their differentiation [176]. GATA-3 has been indicated in the development of
airway eosinophilia and expression is increased in atopic asthma [177] and therefore is an
obvious target for inhibition. Direct inhibition by using a specific antisense oligonucleotide or
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interference RNA promises a novel approach for asthma treatment [178]. Polyphenols, such
as apigenin and quercetin, ameliorate asthma symptoms, and suppress the translocation of
GATA-3 in the cytosol of lung tissue of OVA-sensitized and -challenged mice [179].
NFAT transcription factor is mostly involved in the production of Th2 cytokines through
its  interaction  with  GATA-3  and  activator  protein-1  (AP-1)  [180].  Immunosupressive
drugs cyclosporin A and FK506 block NFAT activation [181]. The use of peptides known
as  inhibitors  of  NFAT-calcineurin  association  (INCA)  represents  an  alternative  asthma
treatment strategy [182].
PPARs are transcription factors belonging to the nuclear receptor superfamily activated by
PUFA derivatives, oxidized fatty acids and phospholipids. PPARγ activation might exhibit
anti-inflammatory properties in different inflammatory processes. In a murine model of
asthma, treatment with PPARγ ligand ciglitazone significantly reduces AHR and lung
inflammation [183]. PPARα and PPARγ ligands also decreases allergen-induced AHR, lung
inflammation as well as serum IgE levels in different asthma models [184]. Popular anti-
asthmatic Traditional Chinese Medicine San-ao Decoction (SAD), comprising Herba Ephedrae,
Radix et Rhizoma Glycyrrhizae and Seneb Armeniacae Amarum, has a significant effect on
PPARγ activation [185].
3.3. Inhibitors of oxidative stress
Oxidative stress plays a critical role in the development of asthmatic conditions. Oxidative
stress and its by-products drive a Th2-dependent immune response. A number of antioxidants
have been explored for their anti-inflammatory and anti-asthmatic properties, and a number
of natural products have emerged as promising candidates. Resveratrol, a component of red
wine, possesses anti-inflammatory and antioxidant properties. It inhibits inflammatory
cytokines release in patients with chronic obstructive pulmonary diseases (COPD) [186] and
may be beneficial in asthma. Several other biological compounds such as Sanguisorba offcina‐
lis [187], aqueous extract from the root of Platycodi Radix [188], stem and bark of Ulmus
davidiana [189], and Alpinia katsumadai seed extracts [190] attenuate oxidative stress and
asthmatic activity in OVA-induced murine asthma. The flavonoids and polyphenols are the
main groups of compounds that display anti-oxidative properties as listed in table 9.
Phytochemicals Function and effective concentration(s) References
Flavonoids
Apigenin Suppresses LPS-induced NO production in RAW264.7 macrophages [191]
Baicalein Inhibits LPS-induced NO production and iNOS expression inRAW264.7 macrophages [192]
Chrysin Inhibits NO production (IC50 7.50±1.84 μM) in LPS-activatedRAW264.7 macrophages [74]
Fisetin Inhibits TNF-induced ROS production in HEK cells [123]
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Phytochemicals Function and effective concentration(s) References
Kaempferol Inhibits NO production (IC50 9.83±1.55 μM) in LPS-activatedRAW264.7 macrophages [74]
Kuraridin Inhibits ROS, NO production (20 & 40 μM) and iNOS geneexpression (40 μM) in LPS-activated RAW264.7 macrophages. [66]
Kurarinone Inhibits ROS, NO production (40 μM) and iNOS gene expression (40μM) in LPS-activated RAW264.7 macrophages. [66]
Luteolin Inhibits NO production (4, 8 & 16 μM) in LPS-activated RAW264.7macrophages. [67]
Morin Inhibits NO production (IC50 44.86±1.05 μM) in LPS-activatedRAW264.7 macrophages [74]
Naringenin Inhibits lung iNOS expression in allergen-induced mouse asthmamodel [78]
Quercetin Inhibits NO production (IC50 36.9±1.24 μM) in LPS-activatedRAW264.7 macrophages [74]
Resveratrol Inhibits NO production in mice with acute lung injury (1 mg/kgbody wt.). [85]
Polyphenols
Caffeic acid Reduces ROS levels in BALF of OVA-sensitized and –challenged mice(10 mg/kg body wt. IP). [88]
Curcumin Reduces iNOS expression in lung tissue of OVA-sensitized asthmaticmice. [91]
EGCG Reduces NOS activity in lungs of OVA-sensitized asthmatic guineapigs. [96]
Hydroxytyrosol Inhibits NO2 production as well as iNOS expression in THP-1 cells (50& 100 μM) [104]
Rosmarinic acid Inhibits formation of ROS and RNS in activates macrophages [193]
Helenalin Inhibits iNOS expression in LPS-stimulated macrophages (10 μM) [137]
n-3 PUFA Decreases exhaled NO from asthma patients challenged with miteallergen [194]
Table 9. Phytochemical inhibitors of oxidative stress
4. Experimental models of asthma
Understanding respiratory sensitization mechanisms is the first step to designing therapeutic
agents that may relieve patients of their asthma symptoms. A number of in vitro and in vivo
experimental models are able to reproduce one or more features of allergic response and have
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been studied for a few decades. Animal models of asthma are the best characterized in terms
of the inflammatory and remodeling processes. The use of gene knockout and transgenic
animals and the therapeutic administration of antibodies or pharmacological antagonists/
inhibitors have helped to identify a range of pre-clinical targets for subsequent evaluation in
humans. Small animal models of asthma, using mice, rats and guinea pigs, are most commonly
used. Most of these models are based on active sensitization to an allergen such as OVA via
the airways. In vitro model systems using inflammatory cells and airway-related cell types are
widely used in studies on immuno-biological mechanisms of asthma. A more detailed
description of the most commonly used models of asthma can be found in Table 10.
In Vivo Model Route(s) ofAdministration Primary Effects
OVA-induced allergic
asthma
Intranasal or aerosol
challenge, intrathoracic
inoculation, intradermal
challenge
Increased serum IgE levels, histological changes in airways
including cellular infiltration, mediator release, AHR, and
remodeling.
LPS lung inflammation
model Intranasal
Leukocytes (mainly neutrophils) recruitment to lung within 4 hr
of LPS treatment.
House dust mite exposure
Intraperitoneal
sensitization followed by
inhalational challenge
Increased serum IgE levels, histological changes in airways
including cellular infiltration, mediator release, AHR, and
remodeling.
Infection by Aspergillus
fumigatus
Intraperitoneal
sensitization followed by
inhalational challenge
Increased serum IgE levels, histological changes in airways
including cellular infiltration, mediator release, AHR, and
remodeling.
Ragweed allergen
exposure
Intraperitoneal
sensitization followed by
inhalational challenge
Airway inflammation and AHR.
Infection with Ascaris
suum
Subcutaneous and
intratracheal sensitization,
aerosol challenge
Bronchoconstriction, AHR and cellular infiltration.
In Vitro Cell Model Cell Type Primary Response(s)
Mast cells:
Human mast cells
CD34+-derived primary
mast cells, cord blood
mast cells, skin mast cells,
lung mast cells, LAD2,
LUVA , HMC-1, RBL-2H3
Release of proinflammatory mediators such as histamine,
tryptase, chymase, cytokines, chemokines, leukotrienes, and
prostaglandins.
Rodent mast cells
Bone marrow-derived
mast cells, peritoneal mast
cells
Release of proinflammatory mediators such as histamine,
tryptase, chymase, cytokines, chemokines, leukotrienes, and
prostaglandins.
Eosinophils Primary cells, EoL-1,AML14.3D10
Release of proinflammatory mediators such as ECP, EPO, EDN,
MBP, cytokines, and chemokines.
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In Vivo Model Route(s) ofAdministration Primary Effects
Bronchial epithelial cells Primary cells, NHBE,BEAS-2B
Release of proinflammatory mediators such as cytokines and
chemokines. Morphological changes.
Alveolar epithelial cells Primary cells, A549 Release of proinflammatory mediators such as cytokines andchemokines. Morphological changes.
Monocytes/
Macrophages
Primary cells, Mono-
Mac-6, THP-1, RAW 264.7
Release of proinflammatory mediators such as cytokines,
chemokines, leukotrienes, prostaglandins, ROS, and RNS.
Dendritic cells
Primary cells, U-937,
CD34-DC, Mo-DC, KG-1,
MUTZ-3
Release of proinflammatory mediators such as cytokines and
chemokines.
Table 10. In vivo and in vitro models for asthma studies
5. Evidence for the association between diet and asthma
5.1. Antioxidants
The airways are continuously exposed to oxidants, either generated endogenously by various
metabolic reactions (e.g. from mitochondrial respiration or released from phagocytes) or
derived from exogenous sources (e.g. air pollutants and cigarette smoke). Allergen-activated
inflammatory cells from asthmatic patients produce more ROS than from healthy individuals.
In addition, several inflammatory mediators including histamine, lipid mediators, cytokines,
chemokines, ECP, and EPO are potential stimuli for ROS production in the airways, leading
to asthma exacerbation.
Deficiency of endogenous antioxidant defenses has been reported in asthma [195]. Since a diet
rich in vitamin A or carotenoids, vitamin C vitamin E, and flavonoids, has been associated
with a decreased prevalence of asthma, understanding the relationship between dietary
antioxidants and asthma-associated inflammatory responses has been a recent focus.
5.1.1. Vitamin A and carotenoids
A systemic review and meta-analysis by Allen et al. has shown that dietary vitamin A intake
is significantly lower in asthmatic patients than in healthy subjects [196]. Asthmatic children
have a lower serum vitamin A concentration than healthy controls [197]. Supplementation of
the diet with lycopene, a carotene found in tomatoes and carrots, has a protective effect against
asthma development in a murine model [198].
All-trans retinoic acid (ARTA), a derivative of vitamin A, inhibits airway inflammation in
asthmatic rats. ARTA inhibits total cell counts and the proportion of inflammatory cells in
BALF, suppresses the expression of NF-κB and intercellular adhering molecule-1 (ICAM-1),
and increases the expression of iκB [199]. Retinoid acid also downregulates the expression of
Th1 and Th2 chemokines in monocytes, including macrophage-derived chemokine and IP-10,
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which are all important in the inflammatory process [200]. Airway smooth muscle cell
migration, which contributes to the airway remodeling in chronic asthma is also inhibited by
ARTA [201]. However, excessive intake of vitamin A exacerbates pulmonary hyperrespon‐
siveness in murine asthma model, suggesting that excessive vitamin A may increase the risk
and severity of asthma [202].
Mechanistically, vitamin A may regulate bronchial hyperreactivity by altering the function
and abundance of the muscarinic M(2) receptors in bronchial tissue [203]. Moreover, carote‐
noids may regulate activation of a variety of transcription factors. Treatment of cells exposed
to oxidative stress with β-carotene suppresses oxidative stress-induced activation of NF-κB
and production of IL-6, TNF, and inflammatory cytokines. Carotenoids may influence the
process of apoptosis in healthy cells. While the pro-apoptotic protein Bax is downregulated
after induction of external stimuli, β-carotene is able to increase expression of the anti-
apoptotic protein Bcl-2 in normal cells. In addition, β-carotene exhibits a pro-apoptotic effect
in colon and leukemic cancer cells, and this effect occurs by a redox-dependent mechanism
linked with NF-κB activity. These dual roles of vitamin A, including carotenoids, on apoptosis
provide the capability of carotenoids as an effective anti-inflammatory agent in various
diseases.
5.1.2. Vitamin C
Many observational studies have reported associations between reduced dietary/blood
vitamin C levels and reduced lung functions. Asthmatic children undergoing an exacerbation
have significant lower serum levels of vitamin C [204]. There is a positive correlation between
serum vitamin C levels and asthma development in children (OR=0.72 per mg/dl, 95% CI=0.55,
0.95) [10]. Furthermore, asthma patients have significantly lower vitamin C level in both the
cellular and fluid-phase fraction in induced sputum [205]. Higher maternal intake of citrus
fruits rich in vitamin C during pregnancy is significantly associated with a reduced risk of
allergic inflammation in the offspring [206]. Administration of vitamin C in OVA-challenged
mice decreases AHR, influx of inflammatory cells in BALF and attenuates lung inflammation
[207]. Similarly, high dose vitamin C supplementation significantly reduces eosinophilic
infiltration in BALF and increases the Th1/Th2 cytokine secretion ratio; thus, skewing the Th1/
Th2 balance toward non-allergic Th1 immune response in asthmatic mice [208].
A randomized, placebo controlled, double-blinded crossover trial has shown that vitamin C
supplementation (1500 mg/day) attenuates asthma symptoms. Moreover, exhaled nitric oxide,
urinary leukotriene C4, D4, E4 and 9α, 1β-prostaglandin F2 after exercise are downregulated
[209]. On the contrary, there are also studies showing no significant effect of vitamin C
supplementation on asthma symptoms. For example, in a randomized, placebo-controlled,
double-blind parallel group trial three hundred asthma patients provided with 1 g/day vitamin
C or placebo for 6 weeks do not show any improvements of asthma symptoms [210], therefore,
there is insufficient evidence from randomised-controlled trials to support the use of vitamin
C for asthma treatment [211].
As its mechanism of action, vitamin C may regulate factors that can influence gene expression,
apoptosis, and other cellular functions indicated in inflammation. In fact, vitamin C protects
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against cell death triggered by various stimuli, and major proportion of this protection is
associated with its antioxidant ability [212]. Vitamin C inhibits the AP-1 activation by regu‐
lating MAPK-ERK pathway [213]. Treatment of cells exposed to UV-B irradiation with vitamin
C results in a 50% decrease in JNK phosphorylation, which activates AP-1, therewith inhibiting
the JNK/AP-1 signaling pathways [214]. At present, however, evidence from randomized
controlled trials is insufficient to recommend a specific role for vitamin C in the treatment of
asthma due to variable study design and generally poor reporting system.
5.1.3. Vitamin E
The body of evidence from multiple studies suggests that a positive association between
asthma outcomes and vitamin E intake or serum vitamin E levels. Asthmatic children have
significantly lower serum levels of vitamin E than non-asthmatic children [204, 215]. A
longitudinal birth cohort study has explored association between maternal plasma vitamin E,
fetus and fetal lungs growth, and childhood asthma. The findings have shown that maternal
vitamin E status has a positive effect on the growth of fetus and fetal lungs during early
pregnancy and better asthma outcomes during childhood [216]. Moreover, high maternal
vitamin E intake during pregnancy also reduces the risk of infantile wheeze [206]. Vitamin E
intake is higher in control subjects than in asthma patients [217]. However there is no rela‐
tionship found between serum vitamin E level and asthma [4, 218]. On the other hand,
administration of vitamin E for 6 weeks does not have an effect on asthma features and serum
immunoglobulin levels in adults [219].
Role of Vitamin E has been investigated in animal models of allergic asthma. Administration
of Vitamin E to allergen-challenged mice reduces mitochondrial dysfunction, Th2 cytokines
production, allergen-specific IgE, and expression of lipid mediators in lung leading to
alleviation of asthmatic features [220]. Expression of IL-5 mRNA and protein in lung, and
plasma IgE level are reduced after OVA sensitization and challenge compared to wild type
mice in vitamin E transfer protein knockout mice [221]. Moreover, dietary supplementation
with vitamin E affords variable degree of protection against ozone-induced enhanced airway
response in allergen-sensitized guinea pigs [222]. However, oral α-tocopherol has no protec‐
tive effect on lung response in rat model of allergic asthma. There is no improvement in OVA-
induced AHR, the inflammatory cell infiltrate and histological changes [223]. The observed
opposite effects of vitamin E could be associated with the study design in an animal model of
asthma. The effect of vitamin E deserves further evaluation.
Vitamin E may induce immunological effects via modulation of the functional activity of T
cells and enhancing the phagocytic activity of peripheral granulocytes [224]. A derivative γ-
tocopherol appears to be a more potent anti-inflammatory agent than α-tocopherol. It de‐
creases systemic oxidative stress, cytokine release from monocytes in asthmatic patients, and
inhibits monocyte response to LPS and LPS-induced degradation of IκB and JNK activation
[225]. There is a contradictory study demonstrating that γ-tocopherol elevates inflammation
and ablates the anti-inflammatory benefit of the α-tocopherol by regulation of endothelial cell
signals during leukocyte recruitment in experimental asthma [226]. Dietary tocopherols are
taken up from the intestine and transported via the lymph to the blood and then to the liver.
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In the liver, α-tocopherol is transferred to plasma lipoproteins, resulting in retention of γ-
tocopherol in tissues at 10% that of α-tocopherol. On interpreting these two contradictory
results, one should consider their serum levels with caution since low plasma level of γ-
tocopherol (1.2–7.0 μM) may act as prooxidant, while higher level of γ-tocopherol (19.5 μM at
8 days) exerts antioxidative and anti-inflammatory effects.
5.1.4. Vitamin D
Over the past several years, the role of vitamin D in immunomodulation has been studied and
shown to have a significant impact on innate and adaptive immunity to infections, including
the pathophysiology of allergic asthma. It has been proposed that the increase in allergy and
asthma is a consequence of widespread vitamin D insufficiency which appears to be frequent
in industrialized countries, reflecting the insufficient intake of diet-sourced vitamin D.
The serum vitamin D level is associated with asthma in children as well as adults. A random‐
ized, placebo controlled clinical study with 1024 children suffering from mild-to-moderate
persistent asthma has shown that Vitamin D deficiency ias associated with a higher rate of
severe asthma [227]. There is a significant positive correlation between forced vital capacity
percent predicted and serum vitamin D level children with asthma. Moreover, 91.6% of these
asthmatic children are not sufficient in serum vitamin D level [228]. Low level of vitamin D in
serum are also associated with increased hyperresponsiveness and reduced glucocorticoid
response in adults with asthma [229]. These studies have indicated that the low serum vitamin
D level is related to reduced lung function and higher risk of asthma. Reduced the risk of
asthma exacerbation triggered by acute respiratory tract infection is observed in a vitamin D
supplementation [230]. Higher consumption of vitamin D during pregnancy may reduce the
risk of childhood wheeze and asthma.
One possible mechanism of vitamin D’s protective effect against asthma can be that it inhibits
the maturation process of dendritic cells by suppressing the expression of costimulatory
molecules HLA-DR, CD86, CD80, the maturation marker CD83, and IL-12 which are important
for the recruitment of Th1 cells [231]. Vitamin D also upregulates the expression of IL-10
receptor in dendritic cells, which is an anti-inflammatory cytokine. In addition, it can promote
the production of FoxP3 positive and IL-10 positive regulatory T cells, and induce the release
of IL-10, TGF-β and CTLA-4 [232]. Furthermore, it may reverse steroid-resistance in asthmatic
patients through induction of IL-10 secreting T-regulatory cells [233], and vitamin D has been
shown to regulate expression of many genes in ASM cells, including genes previously
implicated in asthma predisposition and pathogenesis [234].
5.2. Flavonoids
Flavonoids interfere with oxidation of lipids and other molecules and this strong antioxidative
property makes them protective against airway diseases linked to oxidative stress. In fact,
several epidemiologic studies suggest the beneficial effects of flavonoids on asthma. A
population-based case-control study has shown that apple consumption and red wine intake
are inversely associated with asthma prevalence or severity, perhaps due to a protective effect
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of flavonoids [18]. Moreover, a 30-year longitudinal epidemiological study has reported that
the incidence of asthma is lower in populations with higher intake of flavonoids [235].
Flavonoid Subclass Dietary Flavonoids Some Common Food Sources
Anthocyanidins Cyanidin, Delphinidin, Malvidin,Pelargonidin, Peonidin, Petunidin
Red, blue, and purple berries; red and
purple grapes; red wine
Flavanols
Monomers (Catechins):
Catechin, Epicatechin, Epigallocatechin
Epicatechin gallate, Epigallocatechin
gallate
Dimers and Polymers:
Theaflavins, Thearubigins,
Proanthocyanidins
Catechins: Teas (particularly green and
white), chocolate, grapes, berries, apples
Theaflavins, Thearubigins: Teas
(particularly black and oolong)
Proanthocyanidins: Chocolate, apples,
berries, red grapes, red wine
Flavanones Hesperetin, Naringenin, Eriodictyol Citrus fruits and juices, e.g., oranges,grapefruits, lemons
Flavonols Quercetin, Kaempferol, Myricetin,Isorhamnetin
Widely distributed: yellow onions, scallions,
kale, broccoli, apples, berries, teas
Flavones Apigenin, Luteolin Parsley, thyme, celery, hot peppers
Isoflavones Daidzein, Genistein, Glycitein Soybeans, soy foods, legumes
Table 11. Common dietary flavanoids.
Beyond antioxidative effects, flavonoids inhibit the release of histamine and other preformed
granule associated mediators by inhibiting the activation of basophils and mast cells [66].
Flavonoids inhibit synthesis of IL-4, IL-13, and CD40 ligand but initiate generation of new
phospholipid-derived mediators. One of the well-characterized flavonoids, quercetin, inhibits
eosinophilic secretion of Charcot-Leyden crystal protein and ECP in a concentration-depend‐
ent manner. Very recently, Li et al. demonstrated that apigenin exhibits an anti-inflammatory
activity in a murine asthma model and can switch the immune response to allergens toward
the Th1 profile. These findings suggest that flavonoids are anti-allergenic and anti-inflamma‐
tory agents effective in treating/preventing asthma.
Vascular changes are one of the major components of asthmatic pathogenesis. These changes
include an increase in vascular permeability, vascular dilation/engorgement, and vasculogen‐
esis/angiogenesis. Flavonoids and their related compounds have been shown to modulate
expression of HIF-1, VEGF, matrix metalloproteinases (MMPs), and epidermal growth factor
receptor but also inhibit NF-κB, PI3K/Akt, and ERK1/2 signaling pathways [236]. These
observations suggest that flavonoids as well as their related compounds inhibit certain steps
of angiogenesis including cell migration, microcapillary tube formation, and MMP expression.
Many flavonoids have been tested for their anti-asthma effect. Quercetin decreases the
eosinophil recruitment, reduces IL-5 and IL-4 levels, and inhibits NF-κB activation in BALF in
OVA-induced mouse model [237]. It also regulates Th1/Th2 balance by enhancing IFN-γ and
decreasing IL-4 levels in mouse asthma model [179]. Naringenin alleviates airway inflamma‐
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tion and reactivity by decreasing serum total IgE level and IL-4, IL-13 level in BALF and
inhibiting NF-κB activity [78]. Licorice is a Traditional Chinese Medicine, which contain many
flavonoids. Flavonoids extracted from licorice attenuates LPS-induced acute pulmonary
inflammation by inhibiting inflammatory cells infiltration and inflammatory mediator release
[238]. Neutrophils, macrophages and lymphocytes accumulation in BALF, lung TNF and
IL-1β mRNA expression and lung myeloperoxidase activity are reduced; whereas BALF
superoxide dismutase activity is increased [238]. Flavonoids from red algae decrease eosino‐
phil infiltration, levels of TNF, IL-4 and IL-5 in BALF, airway luminal narrowing, AHR and
level of allergen-specific IgE in the serum [239]. A complex mixture of bioflavonoids derived
from purple passion fruit peel extract supplemented to asthma patients in a randomized,
placebo-controlled, double-blinded trial alleviates asthma clinical symptoms, including FVC
and FEV1 [240].
5.3. Resveratrol
Resveratrol scavenges intracellular ROS by inducing and stabilizing antioxidant enzymes such
as catalase, SOD, and glutathione peroxidase hemoxygenase. In addition to its reducing
properties, resveratrol has been shown to attenuate inflammation via inhibition of prosta‐
glandin production [241] and to decrease the phosphorylation of ERK1/2, COX-2 activity, and
activity of various transcription factors including NF-κB, STAT3, HIF-1α, and β-catenin [236].
Resveratrol also inhibits protein kinases (e.g. src, PI3K, JNK, and Akt) and the production of
inflammatory mediators (e.g. IFN-γ, TNF, COX-2, iNOS, CRP and various interleukins).
Recent studies have reported that resveratrol activates sirtuin1 (SIRT1) which is modulates
apoptosis and has been shown to increase longevity in some experimental systems [242]. SIRT1
modulates poly (ADP-ribose) polymerase-1 (PARP-1) activity upon DNA damage. Activation
of SIRT1 by resveratrol leads to a decrease in PARP-1 activity and promotes cell survival, which
can attenuate the inflammatory reaction. We investigated the effects of resveratrol on human
mast cell activation in comparison to the anti-allergic drug tranilast. The results show that
resveratrol inhibits mast cell degranulation, cytokine, chemokine and leukotriene release, and
is more efficacious than tranilast [316].
Resveratrol is able to modulate innate immune response by inhibiting expression of costimu‐
latory molecules (CD80 and CD86) and major histocompatibility complex classes I and II in
bone marrow-derived dendritic cells and inhibit angiogenesis pathway that is mediated
through expression of MMPs, VEGF, cathepsin D, ICAM-1, and E-selectin [236]. These findings
suggest that resveratrol can be a very attractive compound for preventing/treating asthma
since this compound displays multiple therapeutic effects, showing antioxidative, anti-
inflammatory, immune modulating, and vascular protective property.
Resveratrol has been shown to inhibit the airway inflammation and hyperresponsiveness in
OVA-induced mouse asthma by reducing eosinophil/neutrophils infiltration, the levels of IL-4
and IL-5 in plasma and BALF [81]. It can modulate Th1/Th2 balance, polarization of naive
CD4+ T cells to the Th2 phenotype, and the expression of Th2 regulatory transcription factor,
GATA-3 [81]. It also inhibits cytokine release in vitro by alveolar macrophages from patients
with COPD, including IL-8 and GM-CSF [186].
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5.4. Selenium
Selenium is an important molecule in both innate and adaptive immune responses. It stabilizes
activated platelets by inhibiting platelet aggregation and secretion of adenine nucleotide, thus
possibly blocking the release of acrachidonic acid from platelet membrane [243]. In asthma,
platelets participate by acting as inflammatory cells, by releasing mediators, spasmogens and/
or by interacting with other inflammatory cell types [168]. Selenium affects the expression of
endothelial cell adhesion molecules, E-selectin, P-selectin, ICAM-1, VCAM-1, and ELAM-1,
which are crucial in the inflammatory process for recruitment of inflammatory cells into the
target tissue [244].
Some studies have reported that asthma patients have lower selenium level in platelets and
serum compared to healthy controls [245, 246]. While others studies have found no relationship
between serum selenium level and asthma in Japanese and Europe populations [247, 248].
Selenium supplementation studies in mouse OVA-induced asthma models have shown that
selenium has some protective effects on asthma-associated inflammation. Mice with decreased
and increased levels of selenium intake show lower cytokine levels, airway inflammatory cell
infiltration, serum anti-OVA IgE, airway hyperreactivity, and phosphorylated STAT-6 levels
in the lung compared to medium selenium intake [249]. Selenium supplementation does not
show any clinical benefit in adult asthma patients [250].
Despite the data showing positive effects of selenium on some of the pathologies associated
with asthma, there are still some conflicting findings of selenium supplementation in animal
and human studies. Thus the issue regarding selenium is not conclusive.
5.5. Avenanthramides
Avenanthramides (Avns) are extracted from oats and those synthetically prepared exhibit
potent antioxidant properties in vitro and in vivo. The antioxidant activity of Avns is 10–30
times greater than that of oats’ other phenolic antioxidants such as vanillin and caffeic acid.
Avn-C, one of the three major Avns of oats, often comprises about one-third of the total
concentration of Avns in oat grain (although the relative proportion of Avns is highly variable),
it has the highest antioxidant activity in vitro. By far, these Avns constitute the major phenolic
antioxidants present in the oat kernel. The antioxidant activity of Avn-enriched extract of oats
has been investigated in laboratory animals. Supplementing the diet of rats at 100 mg/kg diet
(providing about 20 mg Avns/kg body weight) has been reported to increase superoxide
dismutase (SOD) activity in skeletal muscle, liver, and kidneys, and to enhance glutathione
peroxidase activity in heart and skeletal muscles [251]. Supplementation at 200 mg/kg diet,
which provides about 40 mg Avns/kg body weight in rats, attenuated the exercise-induced
production of ROS [251].
In addition to demonstrating antioxidant activity, Avn compounds may also interact with
cellular components, through their interactions with the molecular and signaling pathways
that govern cellular responses during inflammation. Using the human aortic endothelial cell
(HAEC) culture system, the potentially beneficial health effects of oat Avns was found to be
mediated via modulation of the cellular and molecular processes that are known to play an
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important role in the inflammation of arteries and the development of atherosclerosis [251].
They have been shown to inhibit vascular endothelial cell expression of adhesion molecules,
including ICAM-1, VCAM-1, and E-selectin. Suppression of these adhesion molecules resulted
in inhibition of monocyte adhesion to HAEC monolayers and reduced production of several
inflammatory cytokines and chemokines, including IL-6, IL-8, and MCP-1, the inflammatory
components involved in fatty streak formation in arteries. The production of proinflammatory
cytokines, chemokines, and adhesion molecules by endothelial cells has been shown to be
regulated by redox-sensitive signal transduction involving nuclear transcription factor NF-κB.
The above-observed effects of Avns on HAEC and other cells are reported to be mediated
through inhibition of NF-κB. More recently, dihydroavenanthramide (DHAv), a synthetic
analog of Avn, has been shown to protect pancreatic β-cells from damage via inhibition of NF-
κB. In a series of experiments, Guo et al. determined that suppression of the expression of NF-
κB activity by Avns is mediated via inhibition of the phosphorylation of IKK and iκB, and by
suppression of proteasome activity in endothelial cells [252]. A study by Sur et al. demonstrated
anti-inflammatory activity of Avns in skin, inhibiting the degradation of IκB-α in human
keratinocytes which correlates with decreased activation of NF-κB and subsequent reduction
in IL-8 release [253]. Topical application mitigates skin inflammation in murine model of
contact hypersensitivity and neurogenic inflammation and reduces pruritogen-induced
scratching in murine itch model [253]. Taken together these observations suggest that Avns
are potent anti-inflammatory agents with a potential application in asthma treatment.
5.6. Herbal preparations
Herbs have been used to treat airway diseases including asthma for thousands years in many
nations, especially in Asian and African countries. In recent decades, some Chinese, Japanese,
Indian, and African herbs have been tested for their anti-asthmatic effects.
5.6.1. Boswellia serrata
Boswellia serrata, Indian frankincense, is commonly found in many regions of the world, such
as South Asia, Northern Africa, and Middle East. Traditional medicine using extract made
from sap, has long been used to treat inflammatory diseases [204]. These extracts contain resin,
amino acids, phenols, terpenes, polysaccharides [205] and β-boswellic acid the major active
anti-inflammatory component [206].
Extract of Boswellia Serrata or β-boswellic acid has been reported to inhibit hypersensitivity
reactions by regulating both the humoral and cellular immune systems They decrease primary
antibody synthesis, inhibit polymorphonuclear leukocyte proliferation and infiltration,
enhance the phagocytotic function of macrophages, and suppress the classical and alternate
complement pathways [254, 255] and suppress the inflammation process, one of the critical
pathological features in asthma. It has been shown that β-boswellic acid inhibits the production
of proinflammatory cytokines, including TNF, IL-1, IL-2, IL-6, IL-12 and IFN-γ by suppressing
the activation of NF-κB [256]. It also inhibits histamine release from mast cells challenged with
G protein stimulator c48/80 in a dose-dependent manner [257]. β-boswellic acid can down-
regulate the synthesis of prostaglandins by inhibiting COX-1 in intact human platelets [258].
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The synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4 from rat
peritoneal polymorphonuclear leukocytes, which contribute to bronchoconstriction, and
increased vascular permeability, are reduced by Boswellia Serrata extract as a result of 5-LO
inhibition [259]. These results suggest that Boswellia Serrata might be effective in controlling
the inflammation process and contraction of airway smooth muscle in asthmatic condition by
inhibiting enzymes required for production of proinflammatory mediators and bronchocon‐
strictor.
O OH
O
HO
Boswellia serrata
Preliminary clinical investigation has shown Boswellia Serrata’s potential therapeutic effect
on asthma. In a double-blind, placebo-controlled clinical study [260], 40 patients took 300 mg
of extract daily for six weeks, while a control group received a lactose placebo for the same
period of time. Lung and immune functions were recorded, including dyspnoea, rhonchi,
frequency of attacks, FEV1, FVC, peak expiratory flow rate (PEFR), eosinophil count and
erythrocyte sedimentation rate. In the treatment group 70% of patients and 27% in the control
group showed improvement in terms of recorded physical symptoms and signs. These results
suggest that Boswellia Serrata extract has potential benefit for asthma patients, although the
age for control and treatment group was not perfectly matched. However, there is not enough
evidence to draw a conclusion on the potential use of Boswellia Serrata for treating asthma in
human.
5.6.2. Bromelain
Bromelain is an extract from the pineapple stem, Ananas comosus, containing a mixture of
cysteine proteases, peroxidase, acid phosphatase, protease inhibitors, and calcium, with
cysteine proteases being the main functional components [214].
Bromelain modulates immune responses both in vitro and in vivo. In vitro, it downregulates
mRNA expression of IL-2, IL-4, and IFN-γ in T cells induced by phorbol myristate acetate
(PMA), with the mechanism thought to be the inhibitionof p21ras and subsequent ERK-2 [261,
262]. In a study using peripheral blood mononuclear cells (PBMC), Bromelain decreases the
expression of migration/activation related cell surface markers on leukocyte by proteolysis,
including CD14, CD16, CD21, CD25, CD44, CD45RA, CD62L [263]. In addition, it can dose-
dependently reduce CD25 expression in anti-CD3 antibody-stimulated CD4+ T cells, which is
upregulated when T cells are activated in inflammation, autoimmunity and allergy [264].
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These results indicate that Bromelain may regulate inflammatory process by interfering the
migration and activation of immune cells, primarily T cells. In vivo, Bromelain may inhibit IgG
production and decrease IL-2 gene transcription in spleen, and significantly reduce blood
CD4+ T cell count [262]. In addition, it downregulates IFN-γ mRNA expression in spleen [265].
These results indicate that Bromelain has regulatory effects on the adaptive immunity,
principally by targeting T cell responses.
Bromelain administration via intraperitoneal injection alleviates some of the features of airway
inflammation in the OVA-induced murine asthma model. It reduces the total numbers of
leukocytes, eosinophils, CD4+ and CD8+ T cells in BALF, and decreases IL-13 concentration,
which is a critical mediator for AHR in asthma [266]. In separate study, oral supplementation
has been shown to suppress airway methacholine sensitivity, decrease IL-13 level, and
eosinophils, CD19+ B cells and CD8+ T cells counts in BAL [267]. These results suggest that
Bromelain modulates airway reactivity by altering the presence of leukocytes in airway, which
is consistent with the in vitro results mentioned above. However, there is no clinical report
available on the use of Bromelain against asthma so far.
5.6.3. Butterbur (Petasites hybridus)
Butterbur is a member of the perennial sunflower family found in Europe and northern Asia.
The ancient Greeks used butterbur roots to treat airway diseases and alleviate bronchial
spasms [268].
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Extract from the flower bud, leaves and root have been shown to inhibit β-hexosaminidase
release, leukotriene C4/D4/E4 synthesis, and TNF production from IgE-sensitized RBL-2H3
cell [223]. A group of Japanese researchers reported that Japanese butterbur contains multiple
active compounds including two eremophilane-type sesquiterpenes, six polyphenolic com‐
pounds, and two triterpene glycosides [223], and based on its inhibitory activity on mast cell
degranulation, fukinolic acid is believed to be the most active component [269]. Another active
component petasin, can reduce leukotriene and ECP production from eosinophils activated
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by platelet-activating factor (PAF) or C5a via suppression of cytosolic phospholipase A2
(cPLA2) activity, decreasing intracellular calcium concentration and inhibiting 5-LO translo‐
cation from the cytosol to nuclear membrane [270]. Pepsin inhibits leukotriene production
from macrophages [271] and suppresses bronchial constriction induced by histamine, carba‐
chol, KCl and leukotriene D4 in isolated guinea pig trachea [272]. In the OVA murine model,
butterbur extract given intranasally together with antigen challenge has been shown to inhibit
airway inflammation induced by OVA and hyperresponsiveness to aerosolized methacholine,
reduce eosinophil count and decrease Th2 cytokine production including IL-4, IL-5 and
RANTES in BALF [227]. These results suggest that Butterbur may have inhibitory effects on
proinflammatory mediator release from a broad range of immune cells.
In 2003, a prescription-based Butterbur extract was approved in Switzerland for the treatment
of seasonal allergic rhinitis and in response some researchers have tested Butterbur extract for
the treatment of asthma. Ziolo et al conducted an open clinical study on its effects on bronchial
reactivity in asthma patients. Provided orally in a single dose for three time periods patients
show significant improvement on FEV1, especially subjects those in longer treatment
group[273]. In another randomized, double-blind, placebo-controlled clinical study, results
have shown that the signs of asthma are significantly suppressed by Butterbur treatment
including FEV1, exhaled NO, serum ECP and peripheral blood eosinophil count, suggesting
Butterbur reduces some of the inflammatory markers associated with allergic respiratory
inflammation [274], However, some long term adverse side effects have ben reported including
abdominal pain, flatulence, and sneezing in pediatric patients and hair loss, cough, dyspnea,
and severe depression for adult patients [230]. More studies with larger sample size are needed
for the evaluation of Butterbur’s clinical use on asthma.
5.6.4. Curcumin
Curcumin is a yellow polyphenol compound, extracted from the rhizomes of Curcuma longa
[231]. In ancient time, curcumin containing turmeric plants were widely used to treat swelling
and wounds in Southern Asia [275].
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Many pharmacological effects of curcumin have been reported, including antioxidative, anti-
inflammatory and antimicrobial activities [276]. In terms of its antioxidative effects, curcumin
is thought to be more potent than vitamin E [277] with the mechanism including downregu‐
lation of NO production, scavenging free radicals, and inducing heme oxygenase-1 to repair
the oxidative damage caused by free radicals [278-280]. Curcumin can inhibit the production
of proinflammatory cytokines such as IL-1β and IL-8, suppress inducible iNOS and NO
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production, and modulate steroid activity. It’s effect on steroid activity may be the result of
inhibition of NF-κB through blocking IKK activity [281-284].
During allergic inflammation, curcumin may modulate both early and late phase responses
by altering Th2 responses. In a murine latex-induced allergy model, characterized by an
increased serum total IgE and latex specific IgG1, elevated peripheral blood eosinophils count,
and enhanced lung tissue IL-4, IL-5 and IL-13, intragastric curcumin administration reduces
lung inflammation. Protein expression of costimulatory molecules CD80, CD86, and OX40-
Ligand, and RNA expression of MMP-9, ornithine aminotransferase (OAT), and thymic
stromal lymphopoietin (TSLP) in antigen-presenting cells are all decreased. These results
suggest that curcumin may disrupt antigen presentation, so that has potential therapeutic
value on allergen triggered airway inflammation [285].
Curcumin has been shown to have anti-asthmatic effects in both in vivo and in vitro studies. In
OVA-induced asthma model in guinea pigs, curcumin treatment during OVA sensitization or
following antigen challenge shows significant protective effects through attenuation of
bronchial constriction and hyperreactivity [286]. This indicates curcumin has both preventive
and therapeutic effects on asthma. In another study in an OVA-induced murine asthma model,
curcumin’s anti-asthmatic function is attributed to the suppression of iNOS and subsequent
NO production, inhibition of inflammatory cytokine synthesis and downregulation of
eosinophil recruitment to airway [91]. In vitro, curcumin supplementation inhibits IgE/antigen
activation of mast cells through the principal activation pathway mediated by FcεRI directly
inhibiting Syk kinase phosphorylation, which is critical for the propagation of signaling
cascade. Subsequently, the phosphorylation of MAP kinases including p38, ERK 1/2 and JNK
are supressed, which are crucial for gene transcription and production of proinflammatory
cytokines [287]. In addition, curcumin inhibits HDM-induced lymphocyte proliferation and
production of IL-2, IL-4, IL-5, and GM-CSF by lymphocytes from asthma patients [246]. These
results indicate that curcumin may attenuate asthma symptom by inhibiting production of
cytokines related to eosinophil function and IgE synthesis, and suppressing IgE-mediated
reactions and hyperreactivity.
5.6.5. Licorice root (Glycyrrhiza glabra)
Licorice root has been widely used around the world to treat cough since ancient time [247].
It contains the active compounds including glycyrrhizin, glycyrrhetinic acid, flavonoids,
isoflavonoids, and chalcones [248]. Glycyrrhizin and glycyrrhetinic acid are considered to be
the main active components [249] and are potent inhibitors of cortisol metabolism, due to their
steroid like structures inhibiting the key steroid metabolic enzymes, delta 4-5-reductase, 11
beta-hydroxysteroid dehydrogenase and 20-hydroxysteroid dehydrogenase [250, 251].
Therefore, the benefits and side effects of steroid are both expected to be enhanced in the
presence of glycyrrhetinic acid and glycyrrhizin.
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The anti-inflammatory effect of glycyrrhizin during virus infection has been well documented
[288-290] and may alleviate allergic inflammation as well. In a contact skin hypersensitivity
mouse model, glycyrrhizin and its metabolite 18 β-glycyrrhetinic acid-3-O-β-D-glucuronide
show protective effects in terms of reduced passive cutaneous anaphylaxis and inflammation,
with glycyrrhizin being more potent than 18 β-glycyrrhetinic acid-3-O-β-D-glucuronide [291].
In an OVA-induced murine asthma model, glycyrrhizin provided orally alleviates airway
constriction and hyperreactivity, pulmonary inflammation. In BAL, IFNγ level is increased,
while IL-4, IL-5 levels and eosinophil count are decreased. It also reduces OVA-specific IgE
levels and upregulates total IgG2a in serum as well [292]. These results indicate that glycyrrhizin
interfere the production of IgE by decreasing the IgE-stimulating cytokines.
The effects of glycyrrhetinic acid and liquiritigenin (a flavonoid of licorice root) on asthma
have been tested both in vivo and in vitro. In vitro, glycyrrhetinic acid and liquiritigenin inhibits
β-hexosaminidase release from RBL-2H3 cells induced by IgE/DNP, and from rat peritoneal
mast cells challenged with c48/80. In vivo, they can suppress c48/80 induced passive cutaneous
anaphylactic reaction in mice. In OVA-induced murine asthma model, glycyrrhetinic acid but
O
COOHHO
O
OO
HOOC
OHHO
HO
HO H3C
CH3
H3C
CH3
CH3
HOOC CH3
O
CH3
Glycyrrhizin
O
OH
HO
O
Liquiritige
Asthma in the 21st Century — Unexpected Applications of Ancient Treatments
http://dx.doi.org/10.5772/56428
313
not liquiritigenin reduces the level of IgE in serum [293]. Flavonoids extracted from licorice
root quench LPS-induced pulmonary inflammation by inhibiting the recruitment of neutro‐
phils, macrophages and lymphocytes in BALF, and suppressing the mRNA expression of TNF
and IL-1β in LPS-challenged lung tissue in mice [238]. The reported side effects of licorice root
includes headache, hypertension, hypokalemia, premature birth, muscle weakness, and
increase body weight, which were attributed to its function on inhibiting the steroid metabo‐
lism [294].
5.6.6. Modified Mai-Men-Dong-Tang
Mai-Men-Dong-Tang is an old Chinese herb formula commonly used for treating lung
diseases, which contains Ophiopogon, Ginseng, Pinellia, Licorice, Jujube, and Oryza [260]. It
is reported to increase the cough threshold to inhaled capsaicin in asthmatic patients. Also, the
eosinophil count in peripheral blood, sputum eosinophil ratio, and serum eosinophil cationic
protein level are significantly decreased, especially in patients with severe airway inflamma‐
tion [261], which suggests that Mai-Men-Dong-Tang may alleviate asthma-related cough by
inhibiting eosinophil function.
Modified Mai-Men-Dong-Tang (mMMDT) contains five herbs, Ophiopogon, American
ginseng, Pinellia, Licorice root, and Lantern tridax [262]. The efficacy and safety of this formula
to persistent, mild to moderate asthma has been evaluated in a double-blind, randomized
clinical study of 100 patients with mild to moderate asthma. After 4 months, improvements in
FEV1 and symptom scores has been reported in mMMDT treatment groups with decreased
serum IgE and no drug-related adverse effects seen in terms of blood test, and liver, kidney
functions [295]. Modified Mai-Men-Dong-Tang is a potential effective herb formula in
treatment of childhood asthma for long time use. However, recommendation cannot be made
because of small sample size used in the study.
5.6.7. Ding-Chuan-Tang
Ding-Chuan-Tang (DCT) is a traditional Chinese herb formula used for the treatment of cough,
wheezing, and chest tightness, developed about four hundred years ago during the Ming
dynasty. This formula contains nine herbs including Radix glycyrrhizae, Tuber pinellia, Gingko
bilboae, Herba ephedrae, Flos tussilaginis farfarae, Cortex mori albae radicis, Fructus perilla frutescens,
Semen pruni armeniacae, Radix scutellariae baicalensis [263]. In OVA-induced pig asthma model,
DCT given orally to animals 30 min before antigen challenge inhibits the antigen induced
immediate asthmatic responses. If it is given together with sensitization, immediate and late
asthmatic responses are all suppressed. In addition, DCT relaxes trachea contracted with
carbachol. The effects are attributed to decreased eosinophil infiltration to airway [263].
Randomized double-blind, placebo-controlled study to assess the effect of DCT on airway
hyperreactivity in children with mild to moderate persistent asthma has shown that the FEV1
is significantly increased in DCT group (196%, p=0.034), but not in placebo control group.
Compared to placebo control group, total clinical/medication score shows improvement in the
DCT group (p=0.004). No side effects have been reported [296]. These results suggest that DCT
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might be effective in treating asthma in children. Larger sample size and wider population are
required in further investigations.
5.6.8. STA-1 and STA-2
STA is a combination of mMMDT and another Chinese herb formula Liu-Wei-Di-Huang-Wan
(LWDHW), which is also used by Chinese as an anti-cough agent. LWDHW contains six herbs
including Rehmannia root, Alisma rhizome, Dioscorea rhizome, Poria, Hoelen, Moutan root bark,
Shanzhu yu. The formula for STA-1 and 2 are the same while the only difference being in the
preparation of LWDHW is different [265]. In a mouse asthma model induced by intraperito‐
neally administrated dermatophagoides pteronyssinus group 5 allergen (Der p 5), oral STA-1
treatment during sensitization suppresses Der p 5-specific IgE production from animals in
response to inhaled Der p 5 challenge. In addition, eosinophil and neutrophil airway infiltra‐
tion, and airway hyperreactivity are all significantly reduced in STA-1 group compared to
control animals [266]. The efficacy and side effects of STA-1 and STA-2 on childhood asthma
treatment have been evaluated in a randomized, double-blind, placebo-controlled study. The
herbs and placebo provided to pediatric patients with mild to moderate asthma reduces
symptom scores, serum steroid concentration, total IgE, and allergen-specific IgE levels and
improves FEV1 in the STA-1 group. STA-2 does not show protective effects. No severe side
effects were reported [297]. These results indicate that STA-1 might be a valuable formula for
childhood asthma, especially subjects induced by dust mite antigen. However, there is not
enough evidence to draw a concrete conclusion. It is worthwhile to evaluate their potential
use as immunotherapy as well.
5.6.9. Anti-Asthma Herbal Medicine Intervention (ASHMI)
ASHMI is a relatively new formula developed by a group of Chinese researchers and physi‐
cians, which is an extract from three herbs: Radix glycyrrhizaen prednisone, Radix sophorae
flavescentis, and Ganoderma [267]. In OVA-induced asthma, oral ASHMI treatment before and
during OVA sensitization and challenge reduces AHR represented by time-integrated change
in peak airway pressure. Eosinophil infiltration in BALF, lung inflammation, OVA-specific IgE
production, and level of IL-4, IL-5, and IL-13 in lung and splenocyte cultures are significantly
lower in ASHMI treated mice, whereas IFN-γ production is increased [267, 268]. A 6-week
treatment of ASHMI beginning 24 hr after the first OVA challenge in mice reduces early phase
response by decreasing histamine, leukotriene C, and OVA-specific IgE levels, and suppresses
late phase responses by decreasing eosinophil count and Th2 cytokines in BALF. In addition,
it relieves contraction of murine tracheal rings by increasing the production of PGI2 [269]. These
results suggest that ASHMI inhibits asthmatic inflammation and airway muscle contraction,
primarily by inhibiting Th2 cell function and might be suitable for treating antigen-induced
asthma in both young and old subjects.
In clinical trial, ASHMI has been shown to improve lung function indicated by increased FEV1
and peak expiratory flow. Clinical symptom scores, use of β2-bronchodilators, serum IgE level,
serum IL-5, IL-13 concentrations are all reduced, and some effects are even better than
prednisone. During the study no adverse effect were recorded [298]. These results indicate the
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effectiveness of ASHMI on treating asthma in both young and old adult patients. More
adequately powered investigations are needed to evaluate ASHMI’s effect on asthma.
5.7. n-3 polyunsaturated fatty acids
PUFA are a group of fatty acids with more than two carbon-carbon double bonds. There are
three types of PUFA, n-3, n-6 and n-9, with their names based on the position of first double
band from methyl end in their chemical structures. Currently, many studies have focused on
n-3 and n-6 PUFA because EPA (20:4 n-3), Dihomo-γ-Linolenic acid (DGLA, 20:3 n-6) and
Arachidonic acid (AA, 20:4 n-6) in cell membrane can be metabolized and become eicosanoid
precursors, which are important modulatory autocrine molecules. Eicosanoids include
prostaglandins, leukotrienes, thromboxanes, resolvins, lipoxins, are signal molecules that exert
complex effects on health. They can modulate inflammation, fever, blood pressure, the
immune system, etc. Eicosanoids can be made by oxidation of twenty carbon n-3 (EPA) and
n-6 (DGLA, AA) PUFA. Eicosanoids from AA are proinflammatory, while those from EPA
and DGLA are less so. There is competition between n-3 PUFA and n-6 PUFA in oxidation in
terms of cyclooxygenase and lipoxygenase, which are critical enzymes for eicosanoid gener‐
ation. AA is the predominant n-6 PUFA in body. In general, n-3 and n-6 are hypothesized to
be beneficial and detrimental respectively [299, 300]. Fish, fish oil, krill, mussel and seal oil are
natural sources of n-3 PUFA.
The major n-3 PUFA are listed in Table 12. In mammals, including humans, n-3 PUFA cannot
be synthesized de novo. Therefore they must be absorbed through the diet or produced from
α-Linolenic acid (ALA), which is an essential fatty acid. Among them, the health beneficial
effects of EPA and DHA (22:6 n-3) are well documented in a broad range of health and disease
conditions. The consumption of EPA and DHA are associated with lower risk of cancer,
hyperlipidemia, and cardiovascular disease, high blood pressure, and neurodegenerative
diseases [301-304]. Their regulating function on immune system was also well known and are
involved in activation of immune cells like of T cells, B cells, mast cells and basophils [305, 306].
In recent decade, the relationship between n-3 PUFA and inflammatory diseases has been
investigated in many studies. In a study conducted in rheumatoid arthritis patients, significant
improvement in symptoms have been reported after 3 month fish oil supplementation in terms
of tender joint count and duration of morning stiffness [307]. Besides reduction in the produc‐
tion of proinflammatory eicosanoids by competition with n-6 PUFA, n-3 PUFA has been found
to be effective in inhibiting the synthesis of proinflammatory cytokines. In fat-1 transgenic
mice, which have a much lower n-6:n-3 PUFA in tissues because they are genetically modified
to possess the ability to convert n-6 PUFA to n-3 PUFA, serum proinflammatory cytokines,
including TNF, IL-1β, and IL-6 are lower. [280]. DHA and ALA also reduce the mRNA
expression of IL-1β, IL-6 in a cerulein-induced pancreatitis model. They inhibit the activation
of AP-1, suppress DNA fragmentation and decrease mRNA expression of apoptotic genes
including p53, Bax and apoptosis-inducing factor in hydrogen peroxide-treated pancreatic
acinar cells [308]. A randomized, double-blind human study has confirmed their suppressing
effect on production of proinflammatory cytokines [309]. It has been shown that n-3 fatty acids
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can alleviate inflammatory process by modulating cell signalling pathways in immune cells,
such as T cell receptor pathway and cytokine receptor pathways. [310-312]
There have been a number of clinical studies that have shown n-3 PUFA’s potentially protective
effects on asthma, especially on childhood patients. There is a positive association between the
n-6:n-3 PUFA in diet and risk for asthma [313]. A randomized, double-blind, placebo-
controlled 3-year study on effect of n-3 PUFA supplementation on asthma has found that high
n-3 PUFA diet intervention significantly reducesd the prevalence of cough in atopic children,
suggesting that n-3 PUFA may be effective in preventing the development of asthma in early
childhood [314]. In a cohort study on the relations between fish/cod oil intake and asthma,
Common name Lipid
name
Chemical name Formula/MW Structure
(HTA) C16:3
(n−3)
all-cis-7,10,13-
hexadecatrienoic acid
C16H26O2/250.376
α-Linolenic
acid (ALA)
C18:3
(n−3)
all-cis-9,12,15-
octadecatrienoic acid
C18H30O2/278.430
α -Parinaric acid C18:4
(n−3)
all-cis-9,11,13,15-
octadecatetraenoic acid
C18H28O2/276.414
Stearidonic
acid (SDA)
C18:4 (n
−3)
all-cis-6,9,12,15-
octadecatetraenoic acid
C18H28O2/276.414
(ETE) C20:3
(n−3)
all-cis-11,14,17-
eicosatrienoic acid
C20H34O2/306.483
(ETA) C20:4
(n−3)
all-cis-8,11,14,17-
eicosatetraenoic acid
C20H32O2/304.467
(EPA) C20:5
(n−3)
all-cis-5,8,11,14,17-
eicosapentaenoic acid
C20H30O2/302.451
(DPA) C22:5
(n−3)
all-cis-7,10,13,16,19-
docosapentaenoic acid
C22H34O2/330.504
(DHA) C22:6
(n−3)
all-cis-4,7,10,13,16,19-
docosahexaenoic acid
C22H32O2/328.488
Table 12. The common name, lipid name and chemical name of major n-3 PUFA
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results have shown that adults with low fish intake frequency (less than weekly) have increased
risk to have asthma [315]. Another randomized double-blind study with 5-weeks n-3 PUFA
supplementation has reported a significant decrease in exhaled NO from asthma patients
challenged with mite allergen. Serum eosinophils count and ECP, and the production of
CysLTs from isolated leukocyte stimulated with mite antigen are also reduced [194]. Overall,
n-3 PUFA might be a promising remedy agents for allergic diseases like asthma but the
mechanism remains to be elucidated.
6. Conclusion
The prevalence of asthma is becoming the mortality and morbidity pandemic of the 21st
century. The cost of in quality of patient’s lives and economic burden of treatment is continuing
to grow at pace unmatched in our current health system. It is impossible to enter public
classroom now without seeing a young sufferer of this condition and any trip to the emergency
department will show how dangerous this disease can be. As the incidence and severity of the
disease continues to rise, medical research is continuing to search new treatment strategies.
While many treatments currently exists those reserve for the severest of conditions carry their
own inherent risk which may match the severity of disease itself. It is for these reasons alone
that health care professionals are now examining the traits of our ancestors in time when this
epidemic was less severe to determine if their medicines and practices hold the answer for the
next treatment strategy. By combining the scientific knowledge at the molecular and clinical
level and the resources of past it might hold the answer to breathless pandemic of the 21st
century.
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